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ABSTRACT 
Kevin Gerald Reuter: POLYMERIC PRINT HYDROGEL NANOPARTICLES:  
NEXT GENERATION DRUG DELIVERY VEHICLES TARGETING CANCEROUS TISSUE 
(Under the direction of Joseph M. DeSimone) 
 
 Standard cancer treatment generally consists of surgery, radiation, and small molecule 
chemotherapies that distribute systemically throughout the body. The systemic distribution of a 
toxic chemotherapeutic commonly produces unwanted side-effects leading to dose-limiting 
toxicity (such as fatigue, hair loss, anemia, nausea, nerve damage, and in some cases death). 
Accompanying the large volume of distribution (Vd) and subsequent dose-limiting toxicity, small 
molecule therapies may display less than desirable pharmacokinetic behavior due to poor 
solubility and low permeability once administered orally or intravenously. Over the last 30 years 
of development, the use of nanoparticulate drug carriers has resulted in lowered Vd, enhanced 
solubility and permeability of the cargo, and improved efficacy in both academic and clinical 
endeavors. In addition, the increased size of a carrier, in comparison to the drug cargo, has been 
observed to enhance permeation and retention into the porous tumor vasculature. However, while 
manufacturing these nano-carriers, issues arise due to intrinsic particle heterogeneity associated 
with common fabrication methods. The use of Particle Replication in Non-wetting Templates 
(PRINT
®
) technology helps overcome this issue and allows for fine control over shape, size, 
modulus, composition, and surface chemistry. In this account, PRINT is employed to fabricate 
nanoparticle carriers that exhibit precisely engineered surface characteristics and size that are 
optimal for tumor deposition. The surface of PRINT hydrogels were precisely functionalized 
with a coating of poly (ethylene glycol), or PEG, that elicited inhibition of protein binding, 
 iv 
macrophage resistance, and a vastly improved blood circulation half-life compared to non-
PEGylated counterparts upon administration in vivo. Upon attachment of an EGFR targeting 
affibody to the terminal end of this PEG group, dramatic changes were observed in vitro and in 
vivo with changes in density of targeting ligand. In addition, a number of different murine cancer 
models were analyzed for passive particle tumor accumulation revealing size and disease model 
dependent neoplastic sequestration, as well as, preferential accumulation in primary and 
metastatic disease sites. Finally, preliminary experimentation with environment-sensitive pro-
drugs linkages revealed site-specific cargo release in dissolution studies. Overall, these efforts 
may lead to improved drug delivery to cancerous tissue and aid in the development of next 
generation drug delivery vehicles.
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CHAPTER 1 NANOPARTICULATE DRUG CARRIERS AS A TREATMENT FOR CANCER 
1.1 A Brief History of Macromolecular-Based Drug Delivery 
Dr. Richard Feynman, the charismatic Nobel laureate, suggested in 1959 that one day we 
could “swallow the doctor”. That lecture, “There’s Plenty of Room at the Bottom”, helped ignite 
a scientific revolution in the field of nanotechnology that continues to this day.
1
 As the 
revolution continues, the question proposed by Feynman remains, “[what if] we can arrange 
atoms the way we want them” and “swallow the doctor”? The medical community is now 
realizing how provocative that lecture was as drug design at the molecular level is beginning to 
benefit the patient in ways previously thought impossible. 
 In the mid-1970’s Helmut Ringsdorf hypothesized that synthetic polymers could promote 
innate therapeutic benefit.
56
 The key idea was unlike low molecular weight therapeutics with 
high pharmacokinetic volume of distribution (Vd) and systemic toxicities, polymers could reduce 
Vd due to cellular internalization being limited to endocytosis rather than diffusion. While 
polymeric drug carriers were already in development, Ringsdorf proposed that by altering an 
intrinsically non-toxic polymer major alterations could be made to its pharmacokinetics, 
pharmacodynamics, and cell-receptor interactions. Additionally, Ringsdorf described several 
polymeric characteristics that may affect these in vivo outcomes: molecular weight (Mw), coil 
structure, co-polymer composition, tacticity, and polyelectrolyte charge. In one fascinating 
example, poly (vinylpyridine)-N-oxides were found to be active against silicosis, a respiratory 
disease caused by breathing in silica dust, a common issue in any chemical laboratory.
66,67
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Unlike low molecular weight isopropylpyridine-N-oxides, the polymer was discovered to protect 
macrophage in the lung from injury by coating the silica particulates, in effect, preventing 
lysosomal membrane interaction, and subsequent rupture. From discoveries just like this, a field 
of synthetically derived therapeutically active polymers originated (Table 1.1). As 
macromolecular therapies against cancer advanced, in the mid-1980’s a discovery was made at 
Kumamoto University Medical School in Japan which spurred the field of nanomedicine. 
Table 1.1 Synthetic Polymers as Cancer Therapeutics* 
Polymer Preclinical Anticancer Activity Reference 
Polyetheneimine (Mw Not reported) Ehrlich ascites via direct antitumor therapeutic 
effect 
57 
Polylysine (Mw = 50 k) Non-lympocytic cell line K562 via direct antitumor 
therapeutic effect 
58 
DEAE-dextran (diethylamino-ethyl-dextran) 
[Mw = 2x10
7
] 
NJA leukemia, JBJ ascites, plasmocytoma, and 
yoshida ascites in vivo 
59 
Poly(Arg-Gly-Asp) [Mw = 10k] Metastasis and migration inhibition of B16-BL6 
melonoma cells via ECM 
60 
Sulfated and carboxymethylated-Chitin 
[Mw = 10-60k] 
Cell attachment and migration of B16-BL6 
melanoma cells via ECM 
61 
Divinyl ether-maleic anhydride copolymer 
[Mw < 18k] 
Stimulates host immune system with L1210 mice 
polymer coupled with decitabine resulted in cures 
62 
Maleic anhydride-ethylene copolymer 
[Intermediate Mw] 
Inhibition of nuceloside uptake in HM5-Carb/S 
melonoma in vivo 
63 
1,3 bis (methylaminocarboxy)-2 methylene 
propane carbamate and N-vinylpyrrolidone 
copolymer [Mw = 5.8k] 
May act via stimulation of host immune system 
against 180 sarcoma, P388 leukemia, and carcinoma 
F0771 in mice, and Walker 1098 in rats 
64 
*Table Adapted from Advances in Polymer Science, Vol. 122 written by D. Putnam and J. Kopecek
65 
 
In 1986, Yasuhiro Matsumura and Hiroshi Maeda made a discovery that reflected the 
revelations of Dr. Feynman with their discovery of the enhanced permeation and retention effect 
(EPR) of tumor vasculature. Utilizing radio-labelled proteins of various sizes, they were able to 
probe the effects of macromolecular size towards tumoritropic accumulation. In these 
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groundbreaking studies, they found that large molecular weight proteins (29,000-160,000 g / 
mol) accumulated preferentially in Sarcoma 180 tumors located on the rear flank of ddY mice in 
comparison to smaller molecular weight proteins (12,000 and 16,000 g / mol). In these 
preliminary experiments, they speculated that the preferential sequestration was due to the 
hypervasculature network of tumors caused by rapid angiogenesis, as well, they proposed that 
the persistence of large macromolecules in tumor tissue could be attributed to an overall lack of 
lymphatic network. These discoveries in the 1980’s spurred an entirely new field of drug 
delivery that exploits preferential tumoritropic accumulation.
2 
Macromolecules were soon conjugated to potent chemotherapeutics in a number of 
polymeric and protein-based matrices and structures. Similar to the macromolecular system 
developed by Maeda, albumin and cage-like viral drug-conjugates were constructed that exhibit 
biologic compatibility and are inert by nature. Micelles and liposomes were one of the first 
nanocarriers developed due to their ability to self-assemble and form a core around the desired 
therapeutic. Along with the encapsulation of drug, liposomes and micelles exhibit 
biocompatibility and facile surface modification if the innate particle characteristics are 
undesirable. Polymeric nanoparticles and dendrimers are remarkable in the diversity of 
therapeutic cargos as both hydrophilic and hydrophobic drugs can be functionalized to the 
carrier.
3
 The vast number of drug delivery systems that have been developed points to how 
impactful the findings of Maeda and Matsumura were. 
1.2 Key Parameters Facilitating Delivery to Solid Tumors 
Current drug delivery vehicles are limited by their physical characteristics as only certain 
particle parameters facilitate successful delivery to solid tumors. Size, shape, modulus, 
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composition, and surface functionality are the key factors that contribute to the interaction of 
nanoparticles and the biological systems they are administered into. These parameters have 
drastic effects on cytotoxicity, reticuloendothelial system (RES) recognition, and how effective 
the carrier penetrates into the diseased mass via the EPR effect. In a broad sense, cytotoxicity 
concerns can be addressed by negating the positive surface charge and tumor penetration can be 
enhanced by limiting particle size to sub-100 nm.
4
 However, there are a number of particle 
parameters that should also be modified in order to evade the reticuloendothelial system (RES) 
responsible for eliminating foreign, “non-self”, entities from the body. Kupffer cells (liver), 
alveolar macrophages (lungs), splenic histiocytes, and systemic macrophages in the blood are 
just a few illustrations of RES cells that are located throughout the body and are responsible for 
nanoparticle clearance.
5
 Along with elimination via RES, mechanical filtration is another route 
for particle clearance, renal clearance is prevalent with particles smaller than 8 nm, liver and 
splenic filtration with rigid particles larger than 200 nm, and biliary excretion with diameters less 
than 30-40 nm (diameter bile duct ~ 30 nm).
6
 With these limits of mechanical filtration in mind, a 
particle of certain physical parameters can be designed that better avoids filtration and 
effectively transports to the site of interest (Figure 1.1).
6
 
 
Figure 1.1 Nanoparticle characteristics for in vivo biocompatibility.
6 
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Blood persistence is paramount for a therapeutic carrier to enhance tumor accumulation. 
The EPR effect is dependent on a long-circulating nanocarrier, as the particles must remain in 
circulation long enough to passively accumulate in the cancerous tissue and release their cargo. 
Size and shape are two important factors in engineering a long-circulating nanoparticle and 
significant work has been conducted to lay the foundation for the appropriate NP size ranges.
4,8
 
The majority of NP shapes are limited to a roughly spherical shape due to a limited availability 
of techniques to produce non-spherical particles. Recently, a number of fabrication technologies 
have been developed that result in shape specificity. Due to this new advancement, the effects of 
particle shape on circulation profiles, cell kinetics, and biodistribution have now been 
studied.
9,10-17
  
 A key factor in particle circulation is the ability to marginate towards the epithelial walls 
within the blood vessels. Margination enhances the probability of the nanocarrier to extravasate 
into the tortuous neoplastic vasculature and significant work has been conducted in this area 
comparing spherical and non-spherical particles of various sizes.
17-20 
Interestingly, higher aspect 
ratios have been shown to marginate more readily than spherical particles (Figure 1.2) and also 
reduce macrophage association when tested in vitro.
11,22,23
 With the higher rate of margination 
and decreased macrophage uptake, particle filtration out of circulation by the RES and 
subsequent sequestration in the liver and spleen is mitigated.
15,22,24
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Figure 1.2 Margination of non-spherical particulates to the vessel wall while spherical counterparts remain in center 
of the blood flow.
17 
 Upon avoiding filtration by the RES, the carrier must passively accumulate in the 
cancerous tissue and effectively extravasate into the diseased tissue. An underreported factor in 
this particle extravasation is the high degree of heterogeneity in the tumor tissue. Not only is 
there dramatic heterogeneity amongst different tumor models and cell-lines, but, significant 
differences exist across a single cancerous mass.
54,55
 The complexity of cancer tissue has spurred 
studies into what particle types penetrate most effectively into solid tumors. Similar to previous 
work in blood circulation profiles, high aspect ratio particles have proven advantageous as they 
penetrate more rapidly into solid tumors when compared to spherical counterparts.
25
 In other 
accounts, high aspect ratio particles also have shown to internalize more readily into cancer cells 
when tested in vitro with HeLa cells.
16 
Across literature, high aspect ratio particles have shown to 
greatly improve a number of key factors that facilitate particulate delivery to solid tumor masses. 
 In the labs of Joseph DeSimone, the benefits of aspect ratio are being studied thoroughly 
with the use of the nanofabrication technique known as Particle Replication in Non-wetting 
 7 
Templates (PRINT). Utilizing PRINT, the DeSimone lab was able to fabricate poly (lactic-co-
glycolic) acid particles of two distinct sizes: 200 nm x 200 nm and 80 nm x 80 nm x 320 nm. In 
these studies, docetaxel was encapsulated within the PLGA matrix at similar concentrations and 
then administered intravenously into mice bearing SKOV-3 human ovarian carcinoma xenografts. 
Both PRINT NP arms outperformed the free drug control, Taxotere, and the 80 x 320 nm type 
enhanced blood and tumor retention while lowering splenic and liver accumulation over the 200 
x 200 nm type.
26
 These advancements in carrier persistence in the blood, avoidance of organ 
filtration, and tumor delivery translated to vastly improved efficacy in an A549 orthotopic 
xenograft model.
27 
In addition to size and shape, particle modulus plays a role in avoiding physical filtration 
as low-modulus particles can circumvent the seemingly stringent size limitations. Red blood 
cells (RBCs) are a great representation of modulus effects in vivo. RBCs are ~8 µm in diameter 
and exhibit extraordinary deformability as they can pass through splenic slits 2-3 µm wide.
28 
Yet 
as the RBCs age, the cells stiffen, are no longer malleable, and are removed from circulation by 
the slits in the spleen. In the DeSimone lab, deformable hydrogel red blood cell mimics 
(RBCMs) were created whose mechanical properties could be modified via cross-linkage density. 
Cross-linker incorporation of 1% by weight into the particle matrix generated a modulus of 
approximately 8 kPa and the resulting blood pharmacokinetic profile was extended dramatically 
exhibiting an elimination half-life on the order of four days.
29
 Filamentous PRINT-based, 80 nm 
x 5000 nm, particles were also fabricated that exhibited similar low cross-link density. These 
particles were able to pass through a 200 nm porous membrane, mimicking the pores found in 
the liver and spleen. However, rigid, asbestos-like, particles were unable to permeate through the 
tight junctions and smaller particles (80 nm x 320 nm, and 80 nm x 180 nm) easily transported 
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through the 200 nm porous membranes independent of modulus.
30
 These optimizations in size, 
shape, and modulus have dramatic effects in vivo and are nevertheless useless without a potent 
therapeutic cargo. 
 New pharmacological drugs are often hydrophobic and poorly-soluble in aqueous media 
meaning they cannot be utilized in vivo without significant formulation. Formulation typically 
consists of adding a number of organic solvents or low molecular weight surfactants in order to 
effectively stabilize the drug prior to administration (Table 1.2).
31
 As expected, these solubilizing 
excipients act as any small molecular weight compound: dispersing throughout the entire body, 
leading to systemic exposure, and resulting dose-limiting toxicities unrelated to the active 
pharmaceutical ingredient (API). Along with solubility, new pharmaceutical compounds are 
typically formulated to have a distinct drug-release profile depending on route-of-administration 
and indication. As with solubility formulation, release kinetics modification can be time-
intensive and have significant monetary restrictions leading to impactful new drug entities never 
coming to market. Nanoparticle-based formulations have the capability of circumventing these 
issues.  
  
 9 
Table 1.2 Common Excipients Used For Oral and Injectable Formulations
31
 
  
Formulation of these APIs within a nano-carrier can overcome issues of stability and 
undesired drug release with relative ease and simultaneously improve PK/PD behavior. With 
nano-formulation, as long as the carrier exhibits solubility in the desired medium, the API will 
mirror that stability without solubilizing excipients. Nanotherapies hold the API within the 
matrix by one of two methods: chemical conjugation or physical entrapment and the release of 
API from the matrix is dependent on the method chosen. Upon particle administration, the API is 
usually kept within the blood compartment, therefore, minimizing the volume of distribution 
(Vd). The Vd is reduced because the carrier cannot easily extravasate through the tightly-packed 
epithelial junctions in the blood vessels like traditional diffusion of small molecules. In 
consequence, deposition in off-target tissues is greatly diminished and a greater amount of the 
injected dose can reach the target tissue. Elimination half-life (t1/2) and overall exposure (area-
under-curve; AUC) are typically improved as well since the API is kept in the plasma 
compartment.  
 10 
The way in which the active therapeutic is coupled to the carrier is an important 
consideration when designing a nanoformulation. Covalent attachment between the carrier and 
cargo typically relies on a release mechanism to free the active therapeutic from the carrier. 
Along with the complexity of chemically modifying the API is the potential benefit of site-
specific release. In numerous accounts throughout literature, cargo detachment has been shown 
to be initiated by both external (light, magnetic fields, and ultrasound) and physiological (pH and 
redox states) stimuli depending on the linker chemistry employed.
32-36
 Extensive development of 
this linker can be undertaken so that the API not only releases at the target-site but also at the 
desired release rate. Ideally, the particulate should present minimal premature release of drug 
before it reaches the intended site, and sufficient release after it reaches the target, in effect, 
reducing systemic deposition and improving efficacy. While covalent linkage offers fine control 
of the cargo, complexity of these systems may defer some to simpler encapsulation methods. 
Traditionally, physical entrapment of the API (encapsulation) is the most utilized method 
of therapeutic attachment due to the ease of formulation. PLGA, a biodegradable, biocompatible, 
and FDA-approved thermoplastic is the most prevalent material used for non-covalent 
encapsulation within nanoformulations. In this composition, hydrophobic drugs are loaded by 
polymeric entrapment or weak intermolecular interactions (such as van Der Waals, hydrogen-
bonding, etc.), and rate of drug release is based upon matrix degradation, drug loading, and 
passive diffusion. Since release is largely diffusion-based, this method lacks precision for what 
environmental conditions elicit drug release and immediate burst release is typically observed 
upon administration. Polymer or lipid coatings can be used to overcome this burst release 
profile.
37
 In the labs Dr. Andrew Wang, a cross-linkable lipid shell was developed to decrease 
the release rate of hydrophobic therapeutics from PLGA NPs. By altering the surface 
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functionality, slower drug release translated to improved efficacy; while NPs lacking a lipid shell 
showed no therapeutic benefit over the free drug.
38
 In general, surface modification is possibly 
the easiest parameter to alter because it can be conducted post-particle fabrication, yet, the 
changes can translate to vastly improved behavior in vivo. 
Surface modification of particulate delivery systems can aid in both passive and active 
targeting to cancerous tissue. Passively targeted particles are typically surface functionalized 
with stealthing agents, to allow for long circulation and thus accumulation through the EPR 
effect. Actively targeted particles are modified with targeting ligands used to recognize 
overexpressed receptors on the tumor cell surface (Figure 1.3).
7 
As previously discussed, passive 
accumulation relies heavily on extending the elimination half-life, thus increasing the probability 
of accumulating within the target site. This is commonly achieved by grafting from, grafting to, 
or adsorbing polyethylene glycol (PEG) to the surface of nanoparticles (PEGylation). While 
other polymers show promise for surface passivation, such as zwitterionic coatings and sugar-
based moieties, PEG remains the dominant choice due to its robust performance, ease of 
attachment, and market availability.
39,40
 Altogether, effects of PEGylation are highly dependent 
on two interrelated parameters: the molecular weight (Mw) and surface density of the PEG 
coating. The density of PEG necessary to promote protein resistance and extend blood 
circulation varies drastically for different nanoparticle types and this will be discussed in greater 
detail in Chapter 2. While passivation remains the most utilized surface modification, active 
targeting has become a fixture in particle platforms.  
 12 
 
Figure 1.3 Active and passive accumulation mechanisms of a nanoparticle platform for cancer therapy.
7
 
The “holy grail” in drug delivery is to transport a highly potent therapeutic to the 
diseased tissue, while completely eliminating exposure to off-target, healthy cells.
41
 With active 
targeting, carriers are surface modified with ligands that bind precisely to unique overexpressed 
receptors on the diseased cell surface. There are a number of neoplastic cell receptors commonly 
targeted: epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), 
and the human epidermal growth factor receptor 2 (HER-2) to name only a few.
42,43
 The 
diversity of targeting agents is just as expansive as the receptors they are directed towards. 
Antibodies, affibodies, small molecules, peptides, and aptamers are just a sampling of targeting 
ligands that have been functionalized to nanoparticles delivery vehicles.
42,44,45
 Engineering an 
actively targeted drug carrier can lead to preferential cell interactions within the diseased tissue, 
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enhanced cell uptake, and efficacy, however, creating an intricate carrier may come with 
unexpected consequences. 
In reality, off-targeting to healthy cells persist due to innate expression of the target-
receptor, albeit to a lesser extent. Dramatic shifts in blood PK, biodistribution, and efficacy have 
also been detected upon ligand attachment, and as with PEGylation, the surface density of 
targeting ligands plays a role in these systematic changes.
45,46
 In one example, cytotoxicity was 
observed towards Ramos cells with an inert transferrin-targeted PRINT particles and the toxicity 
increased as a function of transferrin surface density. In this instance, enhancing multivalency 
(binding affinity associated with multiple ligand-receptor binding sites) produced unprecedented 
cell death for reasons not completely understood.
47 
The size and shape of the carrier can also influence targeting avidity. Theoretical work 
concluded that rod-like particles have greater probability to adhere to the target cell as compared 
to spherical particles.
48
 Computational modeling reflected this by quantifying the increase in 
binding probability with increasing aspect ratio.
49,50
 Experimentally, it was reported that rod-like 
NPs exhibit higher avidity/selectivity toward their target than their spherical analogs in vivo 
(Figure 1.4).
51,17
 Similarly, actively targeting nanoworms enhanced multivalent interactions with 
cell receptors, which amplified their passive accumulation in vivo over spherical nanoparticle 
controls.
52 
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Figure 1.4 The role of nanoparticle shape in binding avidity between the ligand and the target receptor.
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 Precision in particle fabrication is paramount when trying to accurately discern how 
changes in shape and size on the nanometer scale impact behavior upon in vivo administration. 
Most common nanoparticle types (liposomes, micelles, inorganic complexes), while being easier 
to scale and less expensive, sacrifice precise control of these parameters due to their nature of 
particle synthesis. The versatility of PRINT overcomes these limitations and allows independent 
control over particle parameters (size, shape, surface chemistry, modulus, etc.). PRINT has 
produced particles of compositions that range from pure protein to pure chemotherapeutic, 
moduli that span orders of magnitude, and sizes that vary from microns to nanometers, enabling 
the fabrication of a diverse library of NPs. This diversity is only made possible by the atypical 
top-down synthesis of PRINT nanoparticles. 
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1.3 Nanoparticle Fabrication with PRINT Technology 
Nanostructures are typically designed using one of two fabrication platforms. The “bottom-
up” strategy uses atomic or molecular assembly creating macromolecular arrangements, the “top 
-down” strategy utilizes nanostructures fabricated by adding or removing material from a given 
surface. Lithography is one method of top-down fabrication in which nano-scale features can be 
etched onto a master template using similar technology found in the semiconductor industry. 
Particle Replication in Non-wetting Templates (PRINT) uses similar master templates and 
subsequently creates a Teflon-like negative template with distinct cavities of desired size and 
shape. With this mold one can control over particle shape, size, chemical composition, modulus, 
and surface chemistry. This versatility, coupled with its production of calibration-quality 
particles, has driven PRINT to the forefront of nanoparticle control.
16,26,27,29,30,47,53
 The addition 
of a new roll-to-roll (R2R) machine has expanded the PRINT process into a high-throughput 
fabrication technique. 
  The R2R method takes the original batch PRINT process (Scheme 1.1) and transforms it 
to an “assembly-line” (Scheme 1.2), maximizing efficiency and yield. As previously mentioned, 
general PRINT fabrication utilizes a low surface energy mold constructed from a silicon master 
precursor. With the mold in hand, a polymeric solution is deposited onto a high surface energy 
polyethylene terephthalate (PET) sheet and the solvent is allowed to fully evaporate leaving a 
thin polymer film. The thin film is brought into conformal contact with the mold which is then 
passed through a pressurized nip. The nano-sized cavities are then filled with uncured liquid 
polymer via capillary action and, in the case of acrylate-based polymers, the filled mold is photo-
cured with a high-intensity UV-LED oven. After curing, an array of isolated nanoparticles now 
fills the features in the mold with the absence of a flash-layer. The isolated nanoparticles are 
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harvested by means of a sacrificial adhesive film that is later dissolved with a common solvent 
(aqueous or non-aqueous), releasing free PRINT particles. These particles can finally be purified 
from the harvesting solution by simple centrifugation methods and put into a solvent of choice 
for future studies or post-fabrication surface modification. 
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Scheme 1.2 The novel roll-to-roll system allows for high-throughput PRINT NP fabrication. 
First, the mold (A), cover sheet collector (B), and PET delivery sheet (C) are strung up onto 
rollers. The delivery sheet passes through a plasma treater (D) and then PPS is dispensed by a 
syringe pump (E) onto the delivery sheet. The mold and delivery sheet are laminated with a 
heated nip (F) and the filled mold passes through a UV-LED (G). The delivery sheet waste (J) 
and filled mold (H) are collected on rollers while an optional adhesive layer is laminated to the 
mold (I).  
 
  
Scheme 1.1 The roll-to-roll process incorporates each step in the fabrication process A) a Mayer rod and 
pre-particle solution (PPS) deposition controls film thickness onto a high surface energy PET delivery 
sheet B) a heated nip aids in transfer of the PPS to the low surface energy mold cavities and C) transfer 
to the harvesting sheet D) UV-LED photo-cures the PPS leading to polymerized nanoparticles E) R2R 
bead harvester allows for particle collection up to 5-6 ft/min in a compatible solvent. 
 
  
  
B 
A 
C 
D 
E 
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CHAPTER 2 PEGYLATED PRINT NANOPARTICLES: THE IMPACT OF PEG DENSITY ON PROTEIN 
BINDING, MACROPHAGE ASSOCIATION, BIODISTRIBUTION, AND PHARMACOKINETICS
1
 
2.1 Introduction 
The full potential for nanotechnology has yet to surface even after decades of 
groundbreaking research. Nano-based drug delivery systems have produced advancements 
towards next generation cancer therapy (Doxil and Abraxane), but rapid elimination of 
nanoparticles (NPs) from the body continues to mitigate progress.
1-4
 Following intravenous (IV) 
administration, NPs are rapidly removed from circulation and accumulate mainly in the liver and 
spleen, due to opsonization and recognition by the mononuclear phagocyte system (MPS).
2, 5-7
 
There have been many attempts to reduce uptake of nanoparticles by the MPS by controlling the 
physicochemical characteristics of the particles, such as size, surface charge, hydrophilicity and 
surface functionality.
2,5,8-10
 Generally, nanoparticles that have a mean diameter of 200 nm or less, 
with a neutral to negative zeta potential, and an extended hydrophilic polymer surface exhibit 
prolonged blood circulation.
2,5,10, 11
 
Poly(ethylene glycol) (PEG) has been extensively used on a variety of nanoparticle 
systems to increase surface hydrophilicity and improve circulation half-life by decreasing 
interactions with blood proteins and MPS cells.
1,2,6,12-15
 PEGylation can be conducted with 
several unique techniques using di-block PEG derivatives, or by covalently attaching, entrapping, 
or adsorbing PEG chains onto the surface of a nanoparticle.
1,6,14
 The effects of PEGylation are 
                                                 
1
 This chapter previously appeared as an article in Nano Letters. The original citation as follows: 
Perry, J. and Reuter, K. et al. Nano Lett. 2012, 12 (10), 5304-5310. 
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highly dependent on the PEG Mw, polymer chain architecture, and surface density of the PEG 
coating which leads to transitions in PEG conformations at the surface.
13,14,16
 There is a general 
consensus that stealth properties can be achieved by coating with a high density of PEG, with 
MW ranging from 2k to 10k.
14, 17-21
 In spite of PEG extending particle circulation in vivo, there 
is no general standard as to what surface density is needed to accomplish this goal. This stems 
partially from a lack of easy and efficient PEG quantification strategies.  
A number of techniques are currently used to measure degree of PEGylation on NP 
surfaces, yet few have reported precise techniques for PEG quantification on polymeric NPs.
7
 
Most techniques described in literature are qualitative assessments of PEGylation such as NMR 
(PEG peak typically observed ~ 3.65 ppm), dynamic light scattering, and zeta-potential.
22,23
 In 
some instances, PEG surface density is determined by simply assuming complete saturation of 
PEG on the surface of the nanoparticle, and therefore surface PEG density is reported based upon 
PEG size and nanoparticle surface area. For other nanoparticle formulations, PEG is incorporated 
into the nanoparticle matrix and PEG surface coverage is then based upon the weight or mole 
percent of the PEG incorporated – assuming that all the PEG chains are on the surface and not 
embedded within the particle.
14
 Both of these methods typically offer an overestimation of PEG 
grafting. Few quantitative methods exist to accurately determine PEG surface density. 
Chromatography, such as size exclusion chromatography (SEC) and high performance liquid 
chromatography (HPLC), are well-documented quantitation techniques for PEGylated 
liposomes.
6,24
 Thermogravimetric analysis (TGA) is used to calculate PEG weight, but is 
restricted to metallic NPs.
25
 Surface plasmon resonance (SPR) is another method to determine 
PEG loadings with the caveat that quantification is generally characterized on flat substrates.
7
 X-
ray photoelectron spectroscopy (XPS) and Raman analyses can yield detailed information on 
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conformation and quantification, however, these methods are beyond typical analytical 
practices.
7, 21
 Fluorescent assays are commonly used for rapid PEG quantification and are 
amenable for a variety of nanoparticle core compositions.
7,24,26 
PEGylation density is commonly described in terms of the conformation that surface-
bound PEG chains achieve, which is based upon the Flory radius (RF) of the PEG graft, the 
distance (D) between PEG grafts, or the length/thickness (L) of the grafted PEG layer.
7,27,28
 
Based upon these parameters, there are two main conformations that PEG chains can acquire – 
‘mushroom’ or ‘brush’.27,29,30 Mushroom conformation is dictated by having a low density PEG 
coverage, where D > RF, and therefore the PEG chains are not fully extended away from the 
nanoparticle surface, resulting in a thin PEG layer. As D decreases to that of RF, PEG chains 
arrange in a brush conformation, with the PEG chains extending away from the nanoparticle 
surface, resulting in a thick layer. When L > 2RF, the brush conformation was further defined by 
Damodaran et. al. to be a dense brush.
31
 Thus by knowing the three parameters, D, RF, and L, the 
conformation of the PEG chain can be distinguished. Unfortunately, there is a disconnect 
throughout literature as to what parameters are reported. For ease of comparing degree of 
PEGylation, we have compiled data (Table 2.1) from the literature consisting of these key 
parameters and how they affect protein binding, macrophage uptake, and circulation half-life. 
Equations 2.1-2.8 were used to calculate unreported values (see methods section 2.4.5 for 
description of calculations). Based upon this compilation, it appears that the beneficial effects of 
PEGylation (protein and macrophage rejection and enhanced circulation half-life) occur when 
the PEG grafts are in the dense brush regime. 
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Table 2.1 Comparison of parameters used to determine surface PEG density on nanoparticles and their biological 
interactions. 
PEG 
MW 
(g/mol) 
RF 
(nm) 
D       
(nm) 
L       
(nm) 
Regime 
Protein 
Resistance 
Macrophage 
Resistance 
t1/2      
(h) 
REF 
5K 5.96 3.2 8.80 Brush NO NO - 
14
 
5K 5.96 2.8 9.80 Brush - NO - 
46
 
5K 5.96 2.5 10.6 Brush - NO 0.3 
39
 
3.4K 4.76 1.8 8.70 Brush NO - - 
55
 
2K 3.5 2.6 10.2 Dense Brush - YES - 
6
 
5K 5.96 2.2 11.5 Dense Brush YES YES - 
14
 
5K 5.96 2.0 12.4 Dense Brush - YES - 
46
 
5K 5.96 1.8 13.1 Dense Brush - YES 34.3 
39
 
5K 5.96 1.7 13.5 Dense Brush - YES 6 
19
 
3.4K 4.76 1.7 9.50 Dense Brush YES - - 
55
 
5K 5.96 1.3 16.6 Dense Brush YES YES 8.5 
18
 
5K 5.96 0.98 20.0 Dense Brush YES YES 11.3 
18
 
The aim of this study was to evaluate PRINT hydrogel nanoparticles (80 nm x 80 nm x 320 
nm) with varying PEG surface coverage. PEG conformation was determined through standard 
plate-reader analysis of fluorescein-labeled PEG grafts. Herein we report predictive screening 
methods that can rapidly asses the circulation fate of our PEGylated PRINT nanoparticles. We 
explored the use of in vitro assays (protein binding and macrophage uptake) to predict in vivo 
circulation behavior. Intravital microscopy was used to quickly screen the circulation profiles of 
our particles, and a biodistribution study was conducted to look at long time points and confirm 
the results of in vitro assays. 
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2.2 Results and Discussion 
2.2.1 Nanoparticle Fabrication, Surface Modification, and Characterization 
We synthesized calibration quality 80 nm x 80 nm x 320 nm hydrogel particles with a 
narrow polydispersity index (PdI) on a continuous roll-to-roll lab line using the PRINT process 
(Figure 2.1). Utilizing this roll-to-roll method, PRINT particles were successfully made 
continuously at a rate of 360 mg/hour, which also resulted in highly uniform populations of 
particles. Particles were fabricated with amine functional handles (from the amino ethyl 
methacrylate), which were reacted with either a methoxy- or fluorescein-terminated PEG5k-
succinimidyl carboxy methyl ester (PEG5k-SCM). PEG grafting density was controlled by 
varying the PEG5k-to-nanoparticle ratio, and was quantified by fluorescence measurements of the 
fluorescein-PEG5k labeled particles. The fluorescence signal was correlated to the concentration 
of fluorescein-PEG5k with a standard curve. PEG density was calculated based upon the 
concentration of particles in solution and the surface area of hydrated particles (equations can be 
found in supplementary information). PEG density was calculated to be 0.083 ± 0.006 PEG/nm
2
 
and 0.028 ± 0.002 PEG/nm
2
 for the high and low PEG density NPs, respectively (Figure 2.2). In 
these calculations for PEG density, we assumed a uniform layer of PEG on the surface of the 
particle. Even though hydrogel particles swell, leading to possible penetration into the particle, it 
is entropically unfavorable for a large PEG molecule to permeate the hydrogel.  
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Figure 2.1 Scanning electron image of 80 nm x 80 nm x 320 nm PRINT hydrogel nanoparticles, scale bar represents 
500 nm.  
 
Figure 2.2 PEG density quantification of 80 nm x 320 nm particles reacted with 14.0 and 2.0 mg of fluorescein-
PEG5k-SCM resulting in brush (0.083 ± 0.006 PEG / nm
2
) and mushroom (0.028 ± 0.002 PEGs / nm
2
) 
conformations, respectively (n = 6). 
PEG density was converted to the area that one PEG chain occupies (A) and the distance 
between PEG graft sites (D) was calculated (Equation 2.3) to be 3.9 nm and 6.7 nm for the high 
and low PEG density particles, respectively.
32
 As discussed in the introduction, the conformation 
of the PEG grafts is dictated by the relationship between D and RF. The Flory radius (Equation 
2.1) is determined by the number of monomers per polymer chain (N), and the length of one 
monomer (α).29 For PEG5k, α = 0.35 nm and N = 113, therefore RF = 5.96 nm.
33,34
 Based upon RF 
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and D, the PEG polymers were in the mushroom conformation for the low PEG density NPs and 
in the brush conformation for the high PEG density NPs (Figure 2.3). PEG brush thickness was 
calculated (Equation 2.2) to be 7.9 ± 0.1 nm for high PEG density NPs. Based upon Damodaran 
criterion, the high PEG density NPs were not in the dense brush regime.
31
 Hereafter, particles 
will be referred to as PEG mushroom and PEG brush NPs. 
 
Figure 2.3 Cartoon representation of 80 nm x 80 nm x 320 nm PRINT hydrogel nanoparticles with functionalized 
PEG in brush (A) and mushroom (B) conformations. 
 
Equation 2.1 
𝑅𝐹 = 𝑎𝑁
3
5 
Equation 2.2 
𝐿 =
𝑁𝑎
5
3 
𝐷
2
3
 
Equation 2.3 
𝐷 = 2√
𝐴
𝜋
 
For all of the in vitro and in vivo studies, particles were PEGylated using the same 
method outlined above but with a methoxy-PEG5k-SCM. Following PEGylation, the NPs were 
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acetylated to quench any remaining unreacted amines on the particle surface, resulting in 
particles with a slightly negatively zeta potential. The acetylation reaction was necessary because 
nanoparticles with positively charged surface groups typically exhibit higher protein adsorption 
and cell association than neutral or negative groups.
35-37
 After acetylation, particles were 
characterized by dynamic light scattering (DLS) and degree of PEGylation was determined by 
fluorescence (Table 2.2). DLS was used to determine particle hydrodynamic diameter (Dh), PdI, 
and zeta potential. Dh values listed in the table are not indicative of quantitative length scales and 
only act to compare relative trends between different particle types. Calculations for D and L 
were based upon measuring particle dimensions from SEM and AFM images. 
Table 2.2 Nanoparticle characterization based upon dynamic light scattering 
Sample 
Dh 
(nm)
a PdI
a ζ 
(mV)
a 
D 
(nm)
b 
L 
(nm)
b 
non-PEGylated 236.1 ± 4.4 0.063 ± 0.008 -27.9 ± 0.9 - - 
PEG mushroom 341.2 ± 5.3 0.101 ± 0.030 -8.15 ± 0.15 6.7 ± 0.3 5.5 ± 0.2 
PEG brush 347.7 ± 7.7 0.042 ± 0.014 -11.6 ± 0.5 3.9 ± 0.1 7.9 ± 0.1 
a
 Measured by dynamic light scattering 
b
 Calculated from fluorescence analysis 
2.2.2 Protein Binding and In Vitro Assays 
It is well established that phagocytosis is facilitated by the adsorption of plasma proteins 
to NP surfaces, and that varying the surface chemistry of NPs can affect the identity and amount 
of proteins adsorbed.
15,35,36,38-40
 One metric commonly used to characterize ‘stealth’ of 
PEGylated NPs is through in vitro classification including protein binding and/or macrophage 
uptake experiments.
14,19,21,36,39-46
 In an effort to typify our PEGylated PRINT nanoparticles, we 
conducted a comprehensive study of protein binding and macrophage association on NPs with 
varying surface coverage of PEG.  
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Previous reports indicated that varying the surface chemistry of particles can affect both 
the identity and amount of proteins adsorbed.
35,36,46
 Isothermal Titration Calorimetry (ITC) is the 
gold standard for measuring biomolecular interactions and has recently been utilized to 
determine nanoparticle-protein interactions.
47-52
 Following a protocol by Lindman and co-
workers, we used ITC to screen the effect that PEG conformation (mushroom vs. brush) had on 
protein adsorption.
47
 We investigated the interaction of bovine serum albumin (BSA) with non-
PEGylated, PEG mushroom and PEG brush NPs. BSA was chosen as a model protein because 
albumin is the most abundant protein in serum and is typically a major component in the protein 
corona surrounding nanoparticles.
14,35,36,53,54
 The stoichiometry of proteins bound per 
nanoparticle was derived from a simple fit to the data of a one-site binding model using ORIGIN 
software (Figure 2.4). Figure 2.4 shows the amount of protein bound per particle significantly 
decreased with increasing surface PEG density. These results support previous findings where an 
increase in surface PEG density leads to decreased protein adsorption.
14, 42, 43, 46, 55
 However, in 
comparison to literature, we are reporting protein rejection properties at much lower surface PEG 
density.
14
 
 
Figure 2.4 Mass of adsorbed BSA on non-PEGylated, PEG mushroom and PEG brush NPs (n = 3; insert is a 
representative image raw data collected from the isothermal titration calorimetry experiments). 
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The ITC studies clearly indicate that surface PEG density regulated the quantity of 
adsorbed BSA, therefore we hypothesized that it would also regulate the efficiency of 
macrophage uptake. To address macrophage association, nanoparticles were incubated in cell 
culture medium with the MH-S cells. Under these conditions, protein adsorption (from the cell 
culture medium) onto the surface of the nanoparticles can lead to cellular recognition by the 
macrophages and thus initiate uptake. We measured nanoparticle association with macrophages 
as a function of PEG surface density and time (Figure 2.5). At early time points (0.5 to 6 h) the 
PEG mushroom and PEG brush particles behaved the same and were associated with MP-S cells 
4 to 14 times less than non-PEGylated NPs. After 24 h, a slight difference between the PEG 
mushroom and PEG brush NPs became evident. These findings are in agreement with literature; 
as PEG surface coverage increases both protein adsorption and macrophage association 
decreases.
31,35,43,46
 However, as shown in Table 1, these protein/macrophage rejection properties 
are not typically observed until PEG grafts are in the dense brush regime, whereas we observed 
these properties for both PEG mushroom and PEG brush. 
 
Figure 2.5 Percent of MH-S cells associated with non-PEGylated, PEG mushroom and PEG brush nanoparticles 
after various incubation times (n = 3). 
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2.2.3 Circulation and Biodistribution Evaluation 
In an effort to translate in vitro data to circulation time in vivo, intravital microscopy 
(IVM) was utilized to track fluorescent nanoparticles in the ear vasculature of anesthetized mice 
over 2 h. Blood clearance curves of particles with varying surface PEG densities were generated 
from IVM fluorescence measurements (Figure 2.6). The data plot clearly indicates that 
PEGylation is essential for extending circulation times. Both mushroom and brush PEG particles 
appeared to have similar long-circulation profiles, whereas the non-PEGylated particles were 
cleared rapidly. These findings are in line with those observed from the macrophage assay, 
where the PEG mushroom and PEG brush NPs exhibited nearly identical association. 
 
Figure 2.6 Intravital microscopy circulation profiles based upon fraction of maximum fluorescence remaining for 
non-PEGylated, PEG mushroom, and PEG brush nanoparticles. 
In order to distinguish the difference between a mushroom and brush conformation, the 
concentration of particles in blood at longer time points was investigated. Mice were dosed with 
particles and sacrificed at certain time points extending out to 24 h. Figure 2.7 depicts blood 
circulation curves, with accompanying two-compartment PK model fits. The trend among the 
particle types closely follows that of the IVM profiles. The non-PEGylated particles exhibited 
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the same rapid clearance. However, further delineation between a mushroom and brush was 
displayed during the initial time points (> 3 h), with a consistent difference at 24 h.  
 
Figure 2.7 Concentration of nanoparticles in blood over time (n = 4). Data is fit to a two-compartment PK model 
(solid lines) 
Additionally, the MPS organs were resected and analyzed for particle fluorescence, to 
determine if organ accumulation was also dependent on surface PEG conformation. Figure 2.13 
shows the organ accumulation as a function of PEG surface density at 24 h post-injection (organ 
accumulation at earlier time points in Figures 2.8-2.12). The blood concentration of non-
PEGylated particles was undetectable at 24 h. Liver accumulation was high for all particle types, 
but showed decreased uptake as PEG density increased. Furthermore, as PEG density increased, 
so did splenic uptake. This has been observed for other PEGylated polymeric particles compared 
to non-PEGylated particles, where a shift from liver to splenic accumulation was observed.
19, 56, 
57
 It was hypothesized that longer circulation times allow more exposure of the particles to the 
spleen, resulting in higher splenic filtration and uptake by resident phagocytic cells.
57
 Our data 
fits this theory, with a marked increase in splenic fluorescence between non-PEGylated and 
PEGylated particles, and a small increase as PEG density increased further. Thus, while 
 34 
PEGylation increases circulation time via delayed phagocytosis, a particle’s fate is ultimately the 
MPS organs.
19
 While the exact mechanism is still unclear, this trend has been observed for over a 
decade with many particle sizes, shapes and compositions.
1,5,14,30,58,59
 Finally, lung and kidney 
accumulation was minimal and likely attributed to fluorescence in residual blood within the 
organ. 
 
Figure 2.8 Biodistribution of nanoparticles at 0.083 h post-injection, expressed as percent recovered fluorescence per 
organ (n = 4).  
 
Figure 2.9 Biodistribution of nanoparticles at 0.25 h post-injection, expressed as percent recovered fluorescence per 
organ (n = 4). 
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Figure 2.10 Biodistribution of nanoparticles at 0.5 h post-injection, expressed as percent recovered fluorescence per 
organ (n = 4). 
 
Figure 2.11 Biodistribution of nanoparticles at 1 h post-injection, expressed as percent recovered fluorescence per 
organ (n = 4).  
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Figure 2.12 Biodistribution of nanoparticles at 3 h post-injection, expressed as percent recovered fluorescence per 
organ (n = 4). 
 
Figure 2.13 Biodistribution of nanoparticles at 24 h post-injection, expressed as percent recovered fluorescence per 
organ (n = 4). 
Pharmacokinetic (PK) parameters were determined from the blood concentration curves 
for each particle type. Data was subjected to both one- and two-compartment analysis, with 
elimination from the central compartment, using PKSolver. A two-compartment model was 
found to be the best for all three particle types upon comparison of Akaike Information Criterion 
values. Table 2.3 lists the secondary parameters calculated from the primary constants of 
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integration from the two-compartment model. As suggested by IVM data, PEGylation clearly 
extends particle circulation on longer time scales. The half-life (beta-phase) increased from 0.89 
h for non-PEGylated, to 15.5 h for PEG mushroom and 19.5 h for PEG Brush. Clearance and 
AUC (parameters important in drug delivery applications) also increased as PEG density 
increased. A PEG brush surface resulted in a 200-fold and 1.5-fold decrease in clearance versus a 
bare and PEG mushroom surface, respectively. Significant improvements in PK values upon 
PEGylation are widely cited in literature with similar results.
14,57,59
 Furthermore, long-circulation 
half-lives are generally only observed for NPs with a dense PEG brush surface. Again, we have 
shown these same improvements for NPs with PEG mushroom and brush surfaces. 
Table 2.3 Pharmacokinetic parameters from two-compartment model fit of blood concentration data. 
 
t
1/2, α 
(h) 
t
1/2, β 
(h) 
CL 
(mL/h) 
V
d
 
(mL) 
AUC
0-t 
(h*mg/mL) 
non-PEGylated 0.116 0.892 17.5 4.75 0.013 
PEG mushroom 0.144 15.5 0.128 1.40 1.12 
PEG brush 0.478 19.5 0.087 1.48 1.66 
 
Table 2.4 Constants of integration from two-compartmental model fit of blood concentration data with coefficient of 
determination (R
2
). 
 
A α B β R
2
 
non-PEGylated 0.042 5.98 0.004 0.777 0.9996 
PEG mushroom 0.080 4.82 0.075 0.045 0.9977 
PEG brush 0.068 1.45 0.100 0.036 0.9990 
2.3 Conclusions 
We have developed a method for fabricating calibration quality hydrogel nanoparticles 
via a continuous process. This allowed us to conduct comprehensive in vitro and in vivo studies 
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using highly uniform populations of particles and to fully characterize how NPs behave as a 
function of surface PEG density. PEG density was varied using a highly tunable method that 
could easily be quantified by fluorescence. Protein adsorption and macrophage association were 
significantly reduced upon PEGylation of the NPs. An increase in PEG density, resulting in a 
conformation change from mushroom to brush, showed slight improvements in these in vitro 
studies. Extended circulation due to PEGylation was confirmed using IVM, with both PEGylated 
particles behaving similarly. Furthermore, a larger difference in behavior between the two 
regimes became evident through PK and biodistribution analysis. PEGylation resulted in at least 
a 17-fold increase in circulation half-life, a 136-fold decrease in clearance, and an 86-fold 
increase in AUC over non-PEGylated NPs. In conclusion, we show significant improvement in 
overall particle behavior with lower PEG densities than previously reported. 
2.4 Materials and Methods 
2.4.1 Materials 
Poly(ethylene glycol) diacrylate (Mn 700) (PEG700DA), 2-aminoethyl methacrylate 
hydrochloride (AEM), diphenyl (2,4,6-trimethylbenzoyl)-phosphine oxide (TPO), bovine serum 
albumin (BSA) protein standards (2 mg/mL), trypsin, ethylenediametetraacetic acid (EDTA), 
and sucrose were purchased from Sigma-Aldrich. Thermo Scientific Dylight 488, 650 and 680 
maleimide, Thermo Scientific HyClone fetal bovine serum (FBS), PTFE syringe filters (13 mm 
membrane, 0.22 µm pore size), dimethylformamide (DMF), triethylamine (TEA), pyridine, 
sterile water, borate buffer (pH 8.6), Dulbecco’s phosphate buffered saline (PBS) (pH 7.4), 1X 
phosphate buffered saline (PBS) (pH 7.4), acetic anhydride, and methanol were obtained from 
Fisher Scientific. Fluorescein-PEG(5k)-succinimidyl carboxy methyl ester (fluorescein-PEG5k-
SCM) and methoxy-PEG(5k)-succinimidyl carboxy methyl ester (mPEG5k-SCM) were 
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purchased from Creative PEGWorks. Conventional filters (2 μm) were purchased from Agilent 
and polyvinyl alcohol (Mw 2000) (PVOH) was purchased from Acros Organics. PRINT molds 
(80 nm x 80 nm x 320 nm) were obtained from Liquidia Technologies. Tetraethylene glycol 
monoacrylate (HP4A) was synthesized in-house as previously described.
60
 Murine alveolar 
macrophage (MH-S) cells were purchased from American Type Culture Collection.  
2.4.2 Nanoparticle Fabrication 
The PRINT particle fabrication technique has been described previously in detail.
61
The 
pre-particle solution was prepared by dissolving 3.5 wt% of the various reactive monomers in 
methanol. The reactive monomers included: a cure-site monomer (an oligomeric PEG with a 
nominal molar mass of 700 g/mol terminally functionalized on both end groups with an acryloxy 
functionality); a hydrophilic monomer used to make up the majority of the particle composition 
(HP4A); an amine containing monomer (AEM) which served to provide the amine functionality 
used to conjugate PEG onto the surface of the PRINT particles; and in some cases a 
polymerizable fluorescent tag. In all cases a photoinitiator, TPO, was also added. Two different 
pre-particle solutions were used throughout the following studies. For quantifying PEG density 
and ITC studies the pre-particle solution was comprised of 68 wt% HP4A, 20 wt% AEM, 10 wt% 
PEG700DA, and 1 wt% TPO. For the remainder in vitro and in vivo studies, the pre-particle 
solution was comprised of 67.5 wt% HP4A, 20 wt% AEM, 10 wt% PEG700DA, 1 wt% TPO and 
1.5 wt% Dylight maleimide (either 680, 650 or 488). Using a # 3 Mayer rod (R.D. Specialties), a 
thin film of the pre-particles solution was drawn onto a roll of freshly corona treated PET, using 
a custom-made roll-to-roll lab line (Liquidia Technologies) running at 12 ft/min. The solvent was 
evaporated from this delivery sheet by exposing the film to a hot air dam derived from heat guns. 
The delivery sheet was laminated (80 PSI, 12 ft/min) to the patterned side of the mold, followed 
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by delamination at the nip. Particles were cured by passing the filled mold through a UV-LED 
(Phoseon, 395 nm, 3 SCFM N2, 12 ft/min). A PVOH harvesting sheet was hot laminated to the 
filled mold (140 ºC, 80 PSI, 12 ft/min). Upon cooling to room temperature, particles were 
removed from the mold by splitting the PVOH harvesting sheet from the mold. Particles were 
then harvested by dissolving the PVOH in a bead of water (1 mL of water per 5 ft of harvesting 
sheet). The particle suspension was passed through a 2 µm filter (Agilent) to remove any large 
particulates. To remove the excess PVOH, particles were centrifuged (Eppendorf Centrifuge 
5417R) at ca. 21,000 g for 15 min, the supernatant was removed and the particles were re-
suspended in sterile water. This purification process was repeated 4 times. 
2.4.3 Nanoparticle Characterization 
Stock particle concentrations were determined by thermogravimetric analysis (TGA) 
using a TA Instruments Q5000 TGA. TGA analysis was conducted by pipetting 20 µL of the 
stock nanoparticle solution into a tared aluminum sample pan. Samples suspended in water were 
heated at 30 °C/min to 130 °C, followed by a 10 minute isotherm at 130 °C. Samples suspended 
in DMF were heated at 30 °C/min to 170 °C, followed by a 10 minute isotherm at 170 °C. All 
samples were then cooled at 30 °C/min to 30 °C, followed by a 2 minute isotherm at 30 °C. TGA 
was also performed on a 20 µL aliquot of supernatant from a centrifuged sample of the stock 
nanoparticle solution to account for the mass of any stabilizer remaining in each sample. The 
concentration of stabilizer was subtracted from the concentration of stock particle solution to 
determine the actual particle concentration. Particles were visualized by scanning electron 
microscopy (SEM) using a Hitachi S-4700 SEM. Prior to imaging, SEM samples were coated 
with 1.5 nm of gold-palladium alloy using a Cressington 108 auto sputter coater. Particle size 
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and zeta potential were measured by dynamic light scattering (DLS) on a Zetasizer Nano ZS 
(Malvern Instruments, Ltd.).  
Swelling of the particles in an aqueous environment was analyzed using fluid atomic 
force microscopy (AFM) with an Asylum Research MFP-3D atomic force microscope at room 
temperature. Height, phase, and amplitude images were acquired in water, in tapping mode, with 
a silicon nitride cantilever (Budget Sensors, k = 0.06 N/m) at a scan rate of 1 Hz. Samples for 
imaging were prepared by pipetting particle suspension onto a clean glass slide. The solution was 
allowed to evaporate in an effort to settle the nanoparticles onto the glass slide. A droplet of 
water was then placed upon the dried nanoparticles to re-hydrate them. A droplet of water was 
also placed upon the AFM tip. The two droplets were merged and images collected. The 
hydrated dimensions of the particles were then determined from the AFM images. 
2.4.4 PEGylation Quantification 
After purification, the particles were reconstituted in DMF following the centrifugation 
technique outlined above and the concentration of particles in DMF was determined by TGA. 
The particles fabricated contain free primary amine groups which were used as functional 
handles to react with a fluorescein-PEG5k-SCM. The particles (1 mg NPs in 1 mL DMF) were 
reacted with TEA (100 µL) for 10 min at room temperature on a shaker plate (Eppendorf, 1400 
rpm). The fluorescein-PEG5k-SCM was dissolved in DMF and added to the reaction mixture (14 
mg and 2 mg of fluorescein-PEG5k-SCM for high and low PEG density, respectively). A 
deactivated fluorescein-labeled NHS-PEG via addition of ethanolamine was utilized as a 
negative control. The reaction mixture was shaken overnight and then quenched with borate 
buffer (100 μL). The nanoparticle solution was then washed 5 times with DMF via centrifugation. 
The PEGylated particles were characterized by SEM, DLS, and TGA. After conjugating 
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fluorescently-tagged PEG5k to the nanoparticle surface, the amount of PEG bound to the particle 
was assessed via fluorescence measurements. The fluorescein-PEG-NP solution was diluted 1:10 
in borate buffer and pipetted (200 μL) into a Corning 96-well clear bottom plate in triplicate. The 
supernatant from the same nanoparticle solution was added to the 96-well plate using the same 
method. A serial dilution of unconjugated fluorescent-PEG5k was utilized to create a standard 
curve. Fluorescence measurements (λex = 494 nm; λem = 521 nm) of the 96-well plate containing 
the (1) PEGylated nanoparticle (2) supernatant and (3) standard curve were taken using a 
SpectraMax M5 plate-reader. The fluorescence in the supernatant was subtracted from the 
fluorescence observed from the nanoparticle suspension and the final fluorescence measurement 
was correlated to fluorescein-PEG5k concentration through the standard curve. 
2.4.5 PEG Density Calculations 
PEG density was calculated based upon the concentration of particles in solution and the 
surface area of hydrated particles. First, we calculated the total number of PEG molecules and 
nanoparticles in each sample. The number of PEG molecules was calculated from the standard 
curve. The number of NPs was calculated using Equation 2.4, where the mass of NPs per well 
(m) was determined by TGA, the density of the nanoparticle (ρNP) is 1.1 g/cm
3 
and the volume 
(V) determined by measurements from SEM images. Equation 2.5 was used to calculate PEG 
density (S), where the surface area (SANP) of a hydrated 80 nm x 320 nm nanoparticle was 
measured by fluid AFM. The area occupied by each PEG chain (A) is defined by Equation 2.6. 
Assuming that PEG occupies a circular footprint on the particle surface, the distance between 
PEG grafts (D) can be calculated using Equation 2.3.  
Equation 2.4 
#𝑁𝑃𝑆 =  
𝑚
𝜌𝑁𝑃  𝑉𝑁𝑃
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Equation 2.5 
𝑆 =
# PEGs
𝑆𝐴𝑁𝑃
 
Equation 2.6 
𝐴 =
1
𝑆
 
In order to calculate unreported values from referenced literature as seen in Table 1, a 
number of equations were utilized. Equation 2.7 was used explicitly to calculate the area 
occupied per PEG chain (A) for PLGA nanoparticles, where MPEG is the molecular weight of the 
PEG graft, f is mass fraction of PEG in the particle, ρ is the density of the nanoparticle, NA is 
Avogadro’s number, and d is the diameter of the particle.14 Using this value for A, D was then 
calculated using Equation 2.3. Equation 2.8 was used only to calculate D for liposomal particles.
6
 
For this equation Alipid is the area occupied per lipid and m is the mole fraction of PEG 
incorporated in the nanoparticle.
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 For all other nanoparticles listed in Table 1, Equations 2.1-2.3 
were used.  
Equation 2.7 
𝐴 =
6𝑀𝑃𝐸𝐺
𝑑𝑁𝐴𝑓𝜌
 
Equation 2.8 
𝐷 =  √
𝐴𝑙𝑖𝑝𝑖𝑑
𝑚
 
2.4.6 PEGylation and Acetylation for In Vitro and In Vivo Studies 
For in vitro and in vivo studies, particles were PEGylated using the same procedure 
outlined above. However, instead of a fluorescein-PEGK5K-SCM, a methoxy-PEG5K-SCM was 
used. Following PEGylation, particles were acetylated with acetic anhydride to quench any 
unreacted amines and to yield a negative zeta potential. For acetylation, nanoparticles (1 mg NP 
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in 1 mL DMF) were reacted with an excess (10 µL) of pyridine and acetic anhydride (7 µL). The 
reaction was carried out in a sonicator bath (Branson Ultrasonic Cleaner 1.4 A, 160 W) for 15 
min, after which a second addition of acetic anhydride (7 µL) was added and the suspension was 
sonicated for another 15 min. Following acetylation, the particles were washed by centrifugation 
one time in DMF, followed by a borate buffer wash to neutralize any acetic acid side product, 
and then 4 washes with sterile water. Post-acetylation, particles were analyzed by TGA, DLS and 
SEM. 
2.4.7 Protein Binding Using Isothermal Titration Calorimetry  
The isothermal titration calorimetry (ITC) experiments were performed at 37 ºC, using a 
VP-ITC microcalorimeter (GE MicroCal Inc., USA). Experiments were performed by injecting 
20 µM solution of BSA in 1X PBS into a 2 mL sample cell containing nanoparticles at a 
concentration of 2 mg/mL in 1X PBS with a stirring speed of 300. A total of 44 injections were 
performed with a spacing of 240 s and a reference power of 10 μcal/s. Titration volumes of BSA 
were as follows: a first injection of 2 µL, followed by twenty eight injections of 5 µL, and 
fourteen injections of 10 µL. Binding isotherms were plotted and analyzed using Origin Software 
(MicroCal Inc., USA), where the ITC measurements were fit to a one-site binding model. 
2.4.8 Macrophage Association Assay 
Murine alveolar macrophage cells (MH-S) were used to investigate the uptake of 
nanoparticles as a function of surface PEG density. MH-S cells were plated at a density of 
40,000 cells per well in a 24-well plate and were incubated at 37°C for 24 hours. Following 24 h, 
the dye-labeled (Dylight 650 or 680) nanoparticle samples (20 μg in 1 mL water) were incubated 
with the cells for 0.5, 2.5, 6, 24, and 48 h. At the set time points, cells were washed three times 
with 500 μL 1X PBS and detached by the addition of 1X trypsin/EDTA (300 µL) to each well. 
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Following a 5 minute incubation (37°C), 1X DBPS/10% FBS (500 μL) was added to each well 
and was mixed vigorously. This final solution was then transferred to a polypropylene tube and 
analyzed using a Dako CyAn flow cytometer with excitation and emission filters set to match 
that of the fluorescent dye incorporated into the particles. For each sample, 10,000 cells were 
measured. 
2.4.9 In Vivo Studies 
All experiments involving the mice were carried out in accordance with an animal use 
protocol approved by the University of North Carolina Animal Care and Use Committee. Female 
BALB/c mice (18-25 g, Jackson Laboratory) were dosed via tail vein injections of 12.5 mg of 
NPs per kg of mouse weight. The volume of injection ranged from 75 µL to 104 µL of (3 
mg/mL) nanoparticle suspension in an isotonic sucrose solution (9.25 wt%).   
 Intravital microscopy (IVM) was used to assess the circulation profile of the three 
different particle types. Experiments were performed using an IV 100 laser scanning microscope 
(Olympus). The mouse was anesthetized with isofluorane and a tail vein catheter was applied. 
Hair was removed from the ear of the mouse with Nair, and the mouse was placed on a 37 ºC 
heated stage in the prone position and kept under anesthesia. The hairless ear was immobilized to 
an aluminum block with double-sided tape, and vasculature was visualized with a 488-nm laser. 
Mice were then dosed with Dylight 650-labeled NPs with varying PEG surface coverage. 
Fluorescence was measured using a 633-nm laser, and imaging scans were captured every 5 s for 
2 hrs. For circulation analysis, the image files from each scan were exported to ImageJ. 
Following literature procedures, the images were stacked in groups of four, and fluorescent 
signal in each stack was analyzed in the region of interest.
61, 62
 Background corrections were 
obtained using the initial fluorescence in the region of interest before injection. 
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 In an effort to determine circulation half-life, blood draw and biodistribution studies were 
also completed. Injections and tissue/blood collection were performed with assistance of the 
Animal Studies Core (UNC-CH). Mice were dosed with NPs or sucrose (control). For each 
particle type and control, we examined four mice per time point (5 min, 15 min, 30 min, 1 h, 3 h, 
and 24 h). At the various time points post-injection, mice were given a dose of 
ketamine/dexmedetomidine blend to deeply anesthetize them prior to cardiac puncture for blood 
collection. Blood was collected and stored in heparinized Eppendorf tubes (Milian, USA). Mice 
were sacrificed and organs (liver, spleen, kidney, and lung) were harvested, weighed, and 
transferred to 6- or 12-well plates for fluorescence analysis with an IVIS Lumina imager (Caliper 
Life Sciences); excitation and emission filters were set to 675 nm and 720 nm, respectively. 
Heparinized blood was pipetted in 100 µL aliquots into black 96-well plates and imaged on the 
IVIS Lumina. In order to determine particle concentration in the blood, we performed serial 
dilutions (in triplicate) of particles in freshly harvested mouse blood and plotted a standard 
curve. Pharmacokinetic analysis of the blood draw data was performed using PKSolver.
63
 Data 
was fit to either a one- or two-compartment model and the Akaike information criterion (AIC) 
was used to compare goodness of fit for each nanoparticle type.
64
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CHAPTER 3 TARGETED PRINT HYDROGELS: THE ROLE OF NANOPARTICLE SIZE AND LIGAND 
DENSITY ON CELL ASSOCIATION, BIODISTRIBUTION, AND TUMOR ACCUMULATION 
3.1 Introduction 
Passive targeting continues to be the crux of nanoparticle-mediated drug delivery to 
tumor vascular. Improved efficacy typically associated with particulate systems is dependent on 
an improved pharmacokinetic profile compared to the native therapeutic as well as preferential 
accumulation of the carrier within the discontinuous and irregular tumor tissue.
1,3
 This superior 
accumulation is known as the enhanced permeation and retention (EPR) effect, as coined by 
Maeda and Matsumura in the late 1980’s.2 By reducing the carrier size to sub-100 nm 
dimensions and by enhancing plasma retention, neoplastic delivery can be augmented drastically 
due to improved interstitial diffusivity and probability of accretion, respectively.
3
 In order to 
extend circulation time, the carrier must exhibit a neutral or slightly negative surface potential to 
avoid non-specific cell association and surface chemistry adept at evading the mononuclear 
phagocytic system (MPS).
4-9
 Shape is yet another parameter that should be controlled. While 
NPs are typically spherical, recent literature has demonstrated that rod-shaped carriers have 
enhanced cellular internalization both in vitro and in vivo, as well, greater extravasation into and 
accumulation within diseased tissue.
10-12
 Beyond passive targeting, actively targeted 
nanoparticulate systems can further enhance therapeutic effect by preferentially targeting over-
expressed cellular receptors on cancerous tissue.
13-16
 
A distinct advantage offered with particulate-based active targeting is establishing 
multivalent interactions between the carrier and target cell.
17
 Multivalency can lead to enhanced 
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avidity to target cells with traditional low-affinity ligands; therefore, the ligand library is greatly 
expanded when coupled with a particle carrier.
18,25
 In addition, multivalent interactions can 
enhance cell binding several orders of magnitude over the unbound ligand yielding dramatically 
improved payload delivery and tumor reduction.
19
 Particle shape and size also have been shown 
to vary the multivalency effect, with high aspect ratio particulates undergoing cellular 
endocytosis more rapidly than their spherical counterparts.
20
 With these benefits, multivalency 
also comes with a cost of complexity and can lead to significant changes in vitro and in vivo 
from the untargeted counterpart.
 
Determining the optimal density of targeting ligand to epitomize 
multivalent effects remains an arduous task. The impact of finely controlling ligand surface 
density cannot be understated, with noted alterations in toxicity, binding coefficient to the target 
receptor, and tumor accumulation.
15,18, 21-23 
While actively targeting these complex particulate 
systems has become a well-pursued area, off-targeting affects associated with ligand density 
have yet to be fully understood. Depending on the nanoparticle fabrication technique utilized, 
controlling all of the outlined parameters (surface chemistry, shape, size, etc.) simultaneously is 
a challenging if not altogether unobtainable objective.  
To this aim, we investigated the effects nanoparticle size, shape, and targeting ligand 
density in vitro and in vivo. Passive accumulation in tumor tissue was assessed with sphere-like 
and rod-shaped hydrogel PRINT particles to determine the role of NP size and shape. Using a 
FITC-labelled Z
EGFR
 affibody, we delicately controlled ligand density functionalized to both 
particles. Particle shape and size effects on receptor-mediated endocytosis and non-specific 
uptake were observed as ligand density was held constant between both NPs. Biodistribution and 
pharmacokinetics were observed as a function of nanoparticle shape, size, and ligand density. 
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Overall, passive targeting was the dominant factor influencing tumor accumulation while 
changes in ligand density dramatically shifted in vitro and in vivo particle behavior. 
3.2 Results and Discussion 
3.2.1 Passive Targeting: NP Fabrication, Surface Modification, and Characterization 
Calibration-quality hydrogel nanoparticles were synthesized at two sizes: 55 x 60 nm and 
80 x 320 nm (Figure 3.1and Table 3.1). Using a continuous roll-to-roll fabrication system, 
PRINT particles were rapidly fabricated at 72 and 360 mg/hour for 55 x 60 nm and 80 x 320 nm, 
respectively. The particle composition consisted of UV-cured acrylate based monomers. A 
fluorescent marker was included for in vitro (Dylight 488) and in vivo (Dylight 650/680) studies 
in addition to the other acrylate polymeric components. The particle matrix was mainly 
comprised of an HP4A monomer coupled with PEG700DA cross-linker, yielding a PEG-based 
nanoparticle that aids in immune system evasion when administered in vivo.
5,8,28
 An amino 
functional monomer was incorporated to allow for facile post-functionalization chemistry. For 
these studies the primary amine was reacted through NHS (N-Hydroxysuccinimide) chemistry to 
either a monofunctional or bifunctional PEG, for either passive or active tumor accumulation 
studies. The mass of either mono- or bifunctional terminated PEG charged to the hydrogel 
particles resulted in a surface density of PEG sufficient to inhibit macrophage uptake and protein 
opsonization while extending circulation times in vivo. Residual amine groups post-PEGylation 
were converted to inert acetyl groups resulting in a negative NP surface charge, further 
decreasing undesired cellular uptake when administered IV.
28
 As discussed in previous accounts, 
fabrication by PRINT continued to yield calibration-quality nanoparticles that exhibited narrow 
polydispersity post-functionalization.
10,21,27,28,34-36 
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Table 3.1 Nanoparticle characterization via dynamic light scattering 
Type 
(nm) 
Surface Modification 
Dh 
(nm) 
PdI 
ζ 
(mV) 
55 x 70 
- 126.8 ± 4.0 0.130 ± 0.01 +38.0 ± 1.1 
mPEG/acetylation 126.7 ± 2.4 0.095 ± 0.01 -16.7 ± 1.1 
80 x 320 
- 276.6 ± 2.4 0.034 ± 0.01 +35.1 ± 0.9 
mPEG/acetylation 257.3 ± 2.1 0.008 ± 0.01 -19.0 ± 1.1 
 
  
Figure 3.1 Scanning electron micrograph of 80 x 320 nm (left) and 55 x 60 nm (right) hydrogel PRINT 
nanoparticles. 
3.2.2 Assessment of Passive Accumulation as Function of Particle Size 
Nanoparticle size is arguably the most significant factor dictating success of a nano-based 
cancer therapy as passive tumor accumulation is largely regulated on size of the carrier.
30
 To this 
end, sub-100 nm particles have recurrently shown greater accumulation and efficacy than larger 
analogs, as well, general trends indicate tumor uptake is directly correlated to reductions in NP 
size.
31-33
 Yet, previous work from the DeSimone lab has displayed remarkable efficacy in tumor-
bearing mouse models with 80 x 320 nm PLGA NPs.
34-36
 Taking these findings into account, we 
conducted biodistribution studies with non-targeted 55 x 60 nm and 80 x 320 nm hydrogel 
particles in tumor-bearing mice (Figure 3.2). In these studies, the liver exhibited 2-fold greater 
accumulation with 55 x 60 nm particle (42 ± 5%) compared to the 80 x 320 nm particle (18 ± 
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7%), however, the inverse was observed in the spleen with over 2-fold increase with the larger 
rod-shaped particle (72 ± 7%) over the smaller particle (30 ± 7%). Blood retention at 24 h was 
statistically the same between the two NP types while tumor accumulation was dramatically 
enhanced over five-fold with the smaller particle (9.1± 2.5%) compared to the larger particle 
(1.7± 0.7%). These findings coincided with literature as size reduction typically results in more 
dispersed distribution throughout all tissues.
38
 The noteworthy improvement in tumor accretion 
reflects the general trend of enhanced tumor penetration with NP size reduction as previously 
mentioned. This hypothesis is further confirmed as both particles exhibited similar blood 
retention at 24 h; therefore, each NP type exhibits equal exposure to the tumor vasculature and 
equal chance to permeate into the diseased tissue.  
 
Figure 3.2 Biodistribution of PEGylated 80 x 320 nm and 55 x 60 nm NPs at 24 h in A431 tumor-bearing mice 
(inset - enhanced view of blood, tumor, kidney, and lung at 24 h). 
3.2.3 Active Targeting: Conjugation of Ligand at Distinct Surface Densities 
Fabricating actively targeted nano-carriers has shown great precedence improving tumor 
delivery and efficacy.
13-16
 Yet, as discussed previously, the optimal ligand density for a particle 
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platform is reliant on many factors, and changing the targeting density may result in major shifts 
in biodistribution and PK, possibly rendering an advantageous nanotherapy ineffective.
15,23
 In 
effort to preserve the improved biological profile gained by PEG density optimization, it was of 
great importance to study ligand density variation on hydrogel NPs.
28
 To this end, a highly 
tunable and precisely controlled ligand quantitation scheme was developed in an effort to 
delicately vary targeting density on both particle types.  
The targeting conjugation scheme utilized an anti-EGFR affibody, selective to the extra 
cellular domain of the EGFR surface glycoprotein, precisely conjugated to the NP surface at 
several ligand densities (Scheme 3.1). After PEGylating with a thiol-reactive maleimide-PEG5k-
SCM and subsequent acetylation, FITC-labelled affibody functionalized with a non-structural 
cysteine group was reacted to the NP surface. Surface modification concluded with addition of 
mPEG1k-thiol to quench residual maleimide groups with an inert methoxy-functionality. 
Affibody was charged at various amounts to both particle types and the targeting ligand density 
(LG / nm
2
) was quantified by fluorescence methods similar to those previously described for 
quantifying PEG density.
28 
Due to the fine control exhibited, we were able to maintain similar 
ligand density between the two particle sizes at three separate densities. For the 80 nm particle, 
targeting ligand density was calculated to be 0.65, 1.1, 1.8, 3.3, and 4.5 ( x 10
-3
) ligands / nm
2
 
corresponding to ~ 100, 170, 280, 560, and 700 ligands / NP, respectively. For the 55 nm 
particle, densities of 1.2, 2.0, and 3.0 ( x 10
-3
) ligands / nm
2
 were calculated corresponding to ~ 
20, 30, and 40 ligands / NP, respectively (Figure 3.3). For in vitro and in vivo studies, the FITC-
labeled ligand was replaced with an unlabeled analog to reduce possibility of immune 
recognition. Upon dynamic light scattering and zeta-potential analyses, size and PDI were 
observed to increase slightly as a function of targeting ligand density while surface charge 
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neutralized. However, with the 55 nm particle, no distinct trend was observed for size, PDI, or 
surface charge (Table 3.2).  
Scheme 3.1 Conjugation of PRINT NPs to Targeting Ligand 
 
 
2
.5 5 1
0
2
5
5
0
0
1 .51 0 -3
3 .01 0 -3
4 .51 0 -3
6 .01 0 -3
M a s s  C h a rg e d  (µ g )
A
ff
ib
o
d
y
 /
 n
m
2
1
0
2
0
4
0
0
1 .51 0 -3
3 .01 0 -3
4 .51 0 -3
6 .01 0 -3
M a s s  C h a rg e d  (µ g )
A
ff
ib
o
d
y
 /
 n
m
2
 
Figure 3.3 Quantification of targeting ligand on 80 x 320 nm (left) and 55 x 60 nm (right) NPs based upon various 
amounts of fluorescein-labeled Z
EGFR
 affibody charged. 
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Table 3.2 Targeted nanoparticle characterization by dynamic light scattering 
Type 
(nm) 
Surface Modification Dh 
(nm)
a 
PdI
a ζ 
(mV)
a 
Ligand Density 
(LG/nm
2
)
 b 
80 x 320 
Mal-PEG5k /Acetylation 270.1 ± 1.4 0.063 ± 0.022 -24.6 ± 0.4 - 
Methoxy-PEG1k 271.2 ± 0.7 0.017 ± 0.019 -27.4 ± 0.1 - 
2.5 µg LG Charge 270.1 ± 1.7 0.020 ± 0.017 -25.7 ± 0.9 6.5 x10
-4
 ± 1.2 x10
-4
 
5 µg LG Charge 276.1 ± 2.5 0.017 ± 0.012 -25.5 ± 0.6 1.1 x10
-3
 ± 1.5 x10
-4
 
10 µg LG Charge 277.6 ± 2.3 0.015 ± 0.014 -22.0 ± 0.3 1.8 x10
-3
 ± 2.1 x10
-4
 
25 µg LG Charge 290.2 ± 3.7 0.049 ± 0.042 -17.7 ± 0.7 3.3 x10
-3 
± 1.6 x10
-4
 
50 µg LG Charge 295.5 ± 3.8 0.109 ± 0.032 -13.0 ± 1.1 4.5 x10
-3 
± 7.5 x10
-4
 
55 x 60 
Mal-PEG5k /Acetylation 172.7 ± 2.5 0.13 ± 0.019 -17.2 ± 0.3 - 
Methoxy-PEG1k 174.0 ± 1.1 0.15 ± 0.019 -13.6 ± 0.5 - 
10 µg LG Charge 163.2 ± 4.8 0.11 ± 0.017 -14.3 ± 0.2 1.2 x10
-3 
± 2.2 x10
-4 
25 µg LG Charge 170.5 ± 0.8 0.16 ± 0.012 -13.9 ± 0.6 2.0 x10
-3 
± 3.6 x10
-4
 
40 µg LG Charge 165.9 ± 1.6 0.082 ± 0.017 -15.2 ± 0.9 3.0 x10
-3 
± 5.8 x10
-4
 
a
 Measured by dynamic light scattering 
b
 Calculated from fluorescence analysis 
3.2.4 In vitro Analysis as Function of Particle Size, Shape, and Ligand Density 
In vitro studies were conducted with both 55 x 60 nm and 80 x 320 nm particle types to 
determine ligand density and NP shape/size effects. In these studies, EGFR-overexpressing 
epidermoid carcinoma (A431) and alveolar macrophage (MH-S) cells were used to conduct 
targeted cell association and non-specific uptake experiments, respectively. Trypan Blue (TB) 
typically used as a live/dead stain, was used instead to determine if nanoparticles were 
membrane bound or internalized by cells.  As observed in Figure 3.4, if nanoparticles are 
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membrane bound, the Dylight 488 (from the nanoparticle) forms a FRET pair with the TB, 
shifting the λem of the particle into the PE-Cy5 channel (λem ~ 580 nm). However, since TB 
cannot penetrate through the plasma membrane, upon NP internalization, a FRET pair is not 
formed and the λem remains in the FITC channel (λem ~ 520 nm). In all, four scenarios exist 
between the cell and the dye-labelled particle upon cell sorting and bivariate analysis: non-
association (quadrant 1), membrane bound only (quadrant 2), membrane bound and internalized 
(quadrant 3), and internalized only (quadrant 4).  
 
Figure 3.4 Quadrants upon bivariate analysis of flow cytometry of cell-association with targeted nanoparticles. 
For targeting experimentation, a direct correlation was observed between ligand density 
and cells with nanoparticles bound to the outer membrane and internalized in both NP types 
(Figure 3.5). The rod-shaped type amplified the percentage of cell-membrane interaction at 
higher ligand densities potentially due to enhanced cellular adhesion over the spherical targeted 
counterparts; this observation was previously hypothesized via ligand-receptor binding dynamic 
modeling.
39
 For the 80 nm particle, an optimum ligand density was observed at approximately 
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1.8 x 10
-3
 LG / nm
2
 in the cell population that only exhibited internalized NPs and with a further 
increase in ligand density, the majority of cells displayed NPs both internalized and bound to the 
outer membrane. Upon increasing particle dosage, an enhancement in association was observed 
in all cell populations and particle types (Figure 3.6) while negative controls, PEG and wild-type 
affibody, displayed limited uptake with both particle types. These results seem to indicate a limit 
in receptor-mediated endocytosis at a specific time point, particle dosage, and ligand density. As 
well, particle multivalency was proven to be a key factor improving cellular internalization and 
ligand functionalization was shown to be imperative for any significant cell association. Non-
specific uptake studies were conducted to further examine the mechanism of particle 
internalization as a function of targeting density. In general, non-specific uptake with alveolar 
murine macrophage displayed negligible association with either set of particles, however, a 
significant boost in association was found at the highest ligand density for 80 nm type (Figure 
3.7). Additionally, mean fluorescence intensity increased with respect to ligand density for the 
rod-shaped NP type, further indicating a correlation exists between ligand density and non-
specific macrophage interaction with rod-like nanoparticles (Figure 3.8). 
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Figure 3.5 In vitro association of A431 cell population upon incubation with targeted 80 x 320 nm (top) and 55 x 60 
nm NPs (bottom). Two cell populations are shown, one with NPs both bound to the outer cell membrane and 
internalized (left) and a second population with NPs only internalized (right). 
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Figure 3.6 Sub-populations A431 cell interactions with 80 x 320 nm particles at five different targeting ligand 
densities and various dosages. 
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Figure 3.7 Percent association of alveolar macrophage cells (MH-S) with targeted 80 x 320 nm (left) and 55 x 60 nm 
(right) at three distinct ligand densities. 
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Figure 3.8 Average mean fluorescence intensity of alveolar macrophage cells (MH-S) associated with targeted 80 x 
320 nm (left) and 55 x 60 nm (right) at three distinct ligand densities. 
To confirm particle association observed was due to EGFR-mediated endocytosis, a 
competition study was completed. A distinct trend was observed upon which an increase of free 
affibody concentration in cell culture led to a precipitous reduction in particle association 
indicating a direct dependence on the receptor-mediated endocytosis pathway for particle 
internalization (Figure 3.9). In all, these results suggest favorable non-specific uptake with rod-
shaped NPs compared to the sphere-like type since ligand density was held roughly constant 
between both. Similar to previous accounts, an increase in non-specific association trended with 
ligand density, alluding to enhanced opsonization from de-shielding of PEG coating by proteins 
in media.
23
 The cationic nanoparticles, serving as a positive control, displayed near complete 
cellular association which is expected due to the strong interaction between the negatively 
charged cellular membrane and the positive surface charge of amine-functional NPs; this 
interaction also falls in line with previous literature accounts.
5
 The PEG and wild-type, serving 
as negative controls, showed limited interaction with the EGFR-over expressing cell-line. Based 
on these in vitro findings, it was clear that alterations in ligand density led to significant changes 
in target (A431) and phagocytic cellular interactions. Murine biodistribution studies were then 
conducted to elucidate how these in vitro results translate to in vivo behavior.  
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Figure 3.9 A431 cell association of 80 x 320 nm particles (ligand density = 1.1 x10
-3 
LG/nm
2
) with pre-dose of free 
affibody administered at five different concentrations 30 min. prior to particle addition.  
3.2.5 Assessment of Biodistribution and Pharmacokinetics of Targeted Particles 
Biodistribution and blood pharmacokinetics were monitored as a function of targeting 
ligand density on the 80 x 320 nm hydrogel particle. In general, all targeted NP arms displayed 
significant reductions in their pharmacokinetic profiles in comparison to the non-targeted PEG 
control (Figure 3.10 and Table 3.3). The reduction in PK profiles was in direct correlation with 
targeting ligand density as circulation half-life decreased from 11.2 h with the PEG control to 
3.9, 3.3, and 0.7 h with increasing ligand density. The observed area-under-the-curve showed 
substantial reductions over the PEGylated control, with 5- and 28-fold AUC reductions at the 
lowest and highest ligand densities, respectively. Clearance rates were drastically increased over 
the PEG control with 5- and 30-fold increases for the lowest and highest ligand densities, 
respectively. These findings corroborated with previous accounts in literature that describe 
enhanced non-specific binding with ligand density increase.
23
 Based upon these PK profiles the 
targeting ligand density was optimized for biodistribution studies in A431-tumor bearing mice 
(Figure 3.11). Specifically, the targeting density at 4.5 x 10
-3
 LG/nm
2
 was not pursued due to the 
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precipitous reduction in blood PK. A 24 hour biodistribution study revealed vast differences in 
particle sequestration as a function of targeting ligand density. A shift from spleen to liver 
deposition was observed with targeting density enhancement which could be due to innate high 
expression of EGFR in liver tissue.
40
 As observed with blood PK analysis targeting density 
greatly impacted blood retention, yet, even with the mitigated blood retention, tumor 
accumulation improved as a function of ligand density indicating possible multivalent effects 
towards the high-expression EGFR cell-line. From these results it was clear targeting density had 
a significant impact on in vivo outcomes. In order to further enhance tumor accumulation, we 
underwent a similar biodistribution study with the smaller 55 x 60 nm, as they exhibited superior 
passive tumor accumulation.  
 
Figure 3.10 Blood pharmacokinetics of 80 x 320 nm NPs at various targeting densities [square = 6.5 x10
-4 
LG/nm
2
 
triangle = 1.8 x10
-3 
LG/nm
2
; inverted triangle = 4.5 x10
-3 
LG/nm
2
] at five time points (0.083, 0.5, 1, 3, and 24 h). 
PEGylated [circle] and wild-type [diamond] used as controls (n = 4).  
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Table 3.3 Pharmacokinetic parameters of targeted 80 x 320 nm NPs 
Ligand Density  
(LG/nm
2
) 
t 1/2 
(h) 
CL 
(mL/h) 
AUC0-t 
(h*mg/mL) 
0.65 x 10
-3
 3.91 0.81 0.38 
1.8 x 10
-3
 3.32 0.92 0.34 
4.5 x 10
-3
 0.68 4.66 0.06 
WT Control 8.19 0.42 0.65 
PEG Control 11.17 0.14 1.70 
 
 
Figure 3.11 Biodistribution of 80 x 320 nm particles at 24 hours. PEGylated and wild-type affibody particles used as 
controls [Low LG = 6.5 x10
-4 
LG/nm
2
; Med LG = 1.1 x10
-3 
LG/nm
2
; High LG = 1.8 x10
-3
 LG/nm
2
]. 
Biodistribution of 55 x 60 nm hydrogel was conducted as a function of targeting ligand 
density in an effort to further enhance tumor accumulation (Figure 3.12). The 55 x 60 nm arms 
exhibited considerably improved tumor accumulation over any of the 80 x 320 nm particle arms 
due to the major increase in passive accumulation. Again, all targeted NPs shifted deposition 
from spleen to liver in comparison to the non-targeted counterparts; however, unlike the larger 
particle, no discernable difference was observed in liver and spleen as a function of ligand 
density. In the tumor tissue, the highest targeting ligand density demonstrated the best 
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accumulation which was statistically similar to the non-targeted PEG control. Even with no 
statistical difference between the two, the Z
EGFR
 affibody-conjugated particles have a 
significantly greater chance of binding and internalizing within diseased cell as previously shown 
in vitro. In order to account for residual blood sequestration in the neo-plastic tissue, tumor:blood 
(T:B) ratios were calculated and a notable trend was observed. A direct relationship was seen 
between ligand density and (T:B) ratio, leading to statistically significant improvements in the 
targeted particle arms over the non-targeted NPs. Similar to the higher aspect ratio particles, 
increasing targeting ligand density seemed to improve tumor accumulation while simultaneously 
sacrificing blood retention.  
 
Figure 3.12 Biodistribution (left) and accumulation ratio between tumor and whole blood (right) with 55 x 60 nm 
NPs at 24 hours. PEGylated and Taq polymerase binder, a bacterial-binding protein, NPs were used as controls 
[Low LG = 1.2 x10
-3 
LG/nm
2
; Med LG = 2.0 x10
-3
 LG/nm
2
; High LG = 3.0 x10
-3
 LG/nm
2
]. 
3.3 Conclusions 
In this account, we have fabricated calibration-quality hydrogel nanoparticles using the 
PRINT technique at two distinct sizes and shapes. Even though remarkable efficacy has been 
previously established with the rod-shaped 80 x 320 nm, we found significantly improved 
passive accumulation with a 55 x 60 nm particle lending to potential improvement in future 
efficacy studies.
 35,36
 In effort to retain improvements in macrophage inhibition, protein 
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resistance, and extended PK profiles previously established with optimized poly (ethylene 
glycol) surface modulation, we developed a method to finely control the surface ligand density 
of an EGFR-binding affibody on the two different PRINT particles.
28
 With the addition of 
targeting ligand, in vitro analysis yielded rapid association in epidermoid carcinoma cell-line that 
was entirely dependent on EGFR receptor-mediated endocytosis, however, non-specific uptake 
was observed in alveolar macrophage with the rod-shaped particle type at high ligand densities. 
In previous studies, an increase in non-specific macrophage uptake correlated with a stark 
reduction in circulation persistence which may help explain the drastic inverse correlation 
observed between ligand density and blood circulation with the 80 x 320 nm particle.
28
 However, 
even with the mitigated blood retention; targeting density had a direct relationship to tumor 
accumulation at 24 hours. Upon targeting the sphere-like 55 x 60 nm particle, the PEGylated 
control and highly targeted counterpart exhibited statistically similar tumor accumulation; 
however, upon accounting for residual blood within the tumor, a distinct trend was observed that 
displayed a direct correlation between ligand density increase and tumor accumulation. Passive 
accumulation remains the major factor dictating neoplastic delivery; however, we established 
that precise control of NP ligand density, size, and shape is paramount when developing an 
effective delivery vehicle.  
3.4 Materials and Methods 
3.4.1 Materials 
2-aminoethyl methacrylate hydrochloride (AEM), diphenyl (2,4,6-trimethylbenzoyl) 
phosphine oxide (TPO), poly (ethylene glycol) diacrylate (Mn 700) (PEG700DA), trypsin, 
ethylenediaminetetraacetic acid (EDTA), and sucrose were obtained from Sigma-Aldrich. PTFE 
syringe filters (13 mm membrane, 0.2 µm pore size), Thermo Scientific Dylight 488, 650, and 
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680, Thermo Scientific immobilized (tris(2-carboxyethyl)phosphine)disulfide reducing gel 
(TCEP), Thermo Scientific HyClone fetal bovine serum (FBS), triethylamine (TEA), acetic 
anhydride, pyridine, 4-(2-Hydroxyethyl) piperazine-1-ethanesulfonic acid (1M HEPES buffer), 
methanol, sterile water, dimethylformamide (DMF), Dulbecco’s phosphate buffered saline (pH 
7.4) (DPBS), 1X phosphate buffered saline (pH 7.4) (PBS), and Dulbecco's Modified Eagle's 
Medium (DMEM) were purchased from Fisher Scientific. Maleimide-PEG5k-succinimidyl 
carboxy methyl ester (Mal-PEG5k-SCM), methoxy-PEG5k- succinimidyl carboxy methyl ester 
(mPEG5k-SCM), and methoxy-PEG1k-thiol (mPEG1k-SH) were all obtained from Creative 
PEGWorks (Winston Salem, NC). Polyvinyl alcohol (Mw 2000) (PVOH) was bought from Acros 
Organics and 2 µm conventional filters were purchased from Agilent Technologies. Borate 
buffer (pH 9.5) was acquired from RICCA Chemical Company. Murine alveolar macrophage 
(MH-S) cells and human epidermoid carcinoma (A431) cells were purchased from American 
Type Culture Collection. PRINT molds (80 nm x 80 x 320 nm and 55 x 60 nm) were acquired 
from Liquidia Technologies. Tetraethylene glycol monoacrylate (HP4A) was synthesized in-
house by previously described methods.
24
 Monomeric EGFR targeting affibody (Z
EGFR1907
), 
fluorescein-labelled analog, and the wild-type affibody control were prepared with methods 
previously described.
26
 
3.4.2 Nanoparticle Fabrication 
The nano fabrication technique, Particle Replication in Non-wetting Templates (PRINT), 
has previously been described in greater detail.
10,27,28
 In this account, our general pre-particle 
solution (PPS) consisted of a 3.5 wt% of cure-site monomer (CSM) in methanol. For studies 
quantifying density of affibody a CSM composition of 69 wt% HP4A (main monomer), 20 wt% 
AEM (functional monomer), 10 wt% PEG700DA (cross-linker), and 1 wt% TPO (photoinitiator) 
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was used. For all in vitro and in vivo studies a CSM composition of 68 wt% HP4A, 20 wt% AEM, 
10 wt% PEG700DA, 1 wt% TPO, and 1 wt% Dylight maleimide (488, 650, or 680; imaging 
agent) was used. In our studies, two different NP types (55 x 60 nm and 80 nm x 80 x 320 nm) 
were fabricated. Using a Mayer rod (#3 for 80 x 320 nm; #2 for 55 x 60 nm) and a standard 
syringe pump (pump rate: 90 mL/h for 80 x 320 nm, 60 mL/h for 55 x 60 nm), a thin film of PPS 
was drawn onto corona treated PET with the aid of a custom large scale roll-to-roll PRINT nano-
fabrication system at 12 ft/min. The methanol was evaporated from the PET delivery sheet using 
two heat guns resulting in a thin monomer film. The delivery sheet was laminated to the nano-
patterned side of mold (either 80 nm x 80 nm x 320 or 55 x 60 nm Teflon-like mold) using a 
pressurized nip (80 PSI), filling the patterned nano-cavities via capillary action, and then 
delaminated. The acrylate monomer mixture was cured in the filled mold upon passing through a 
UV-LED (Phoseon, λ spectral output 395 nm, 3 SCFM N2) yielding cured particles in the mold. A 
PVOH harvesting sheet was laminated to the filled mold, passed through a heated/pressurized 
nip (80 PSI, 160°C, 3 ft/min), cooled to room temperature, and then the harvesting sheet was 
split from the empty mold. The nanoparticle array was collected from the harvesting sheet by 
passing it through a bead of sterile water (4 ft/min; 2 mL water per 10 foot section), in turn, 
dissolving the PVOH and yielding a particle suspension. The NP suspension was passed through 
a 2 µm Agilent filter to remove residual scum layer or particulates. The suspension was further 
purified by centrifugation with an Eppendorf 5417R centrifuge at 7,000 RPM for 20-30 min and 
the pelleted impurities were discarded by decantation from the purified supernatant. Excess 
PVOH was removed by centrifugation at 14,000 RPM (20-30 minutes for 80 x 320 nm, 1-3 
hours for 55 x 60 nm) followed by supernatant removal and resuspension of the NP pellet in 
sterile water. The removal of excess PVOH was repeated three times. 
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3.4.3 Nanoparticle Characterization 
The particle concentration was assessed by thermogravimetric analysis (TGA) on a TA 
Instruments Q5000 TGA. In short, 10 µL of the nanoparticle suspension was pipette into a tared 
aluminum sample pan. The sample was heated to 130°C (30°C/min) and held at isotherm for 10 
minutes. The sample was then cooled to 30°C (30°C/min) and held for a 2 minute isotherm. The 
process was repeated with the supernatant from a centrifuged nanoparticle sample in order to 
account for remaining mass of PVOH in the solution. The particle concentration was determined 
by subtracting the concentration of remaining stabilizer from the original particle solution 
yielding the actual NP concentration of the stock solution. The particles were imaged by 
scanning electron microscopy (SEM) with a Hitachi S-4700 SEM. Before imaging, the particle 
stock solution was diluted (50 µg/mL) in methanol and 2 µL was pipette onto a silicon wafer. 
Using a Cressington 108 auto sputter coater, a 1.5 nm palladium-gold coating was sputtered onto 
the Si wafer and the sample was analyzed. Particle size and zeta potential was determined by 
dynamic light scattering (DLS) after dilution (0.1 mg/mL in water) using a Zetasizer Nano ZS 
(Malvern Instruments, Ltd.).  
The hydrated dimensions of the both particle types were measured by fluid atomic force 
microscopy (AFM) using an Asylum Research MFP-3D atomic force microscope. Height and 
phase retraces were measured in water, in AC mode using a silicon nitride cantilever (Budget 
Sensors, k = 0.06 N/m) at a 1 Hz scan rate and 2 µm scan size. The AFM sample was prepared 
by placing a droplet of suspended nanoparticles on a glass slide and the solvent was allowed to 
evaporate from the sample. With the particles settled on the slide, a droplet of water was placed 
on the sample to rehydrate the NPs and another droplet of water was placed on the cantilever tip. 
The hydrated AFM tip and glass slide were married and the images were collected. The 
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dimensions and subsequent surface area of both particle types (both 80 x 320 nm and 55 x 60 
nm) were measured by using either the phase or height retrace.  
3.4.4 Surface Conjugation of NPs for Non-Targeted Studies 
After particle purification, the suspension was washed into DMF (3x) using the 
centrifugation method (14,000 RPM; 0.5 to 1 h) and concentration was assessed by TGA 
analysis. The particle solution (1 mg; 0.865 mg/mL) was reacted with TEA (100 µL) and shaken 
for ten minutes on a shaker plate at room temperature (Eppendorf; 1400 rpm). Methoxy-PEG5k-
SCM was dissolved in DMF (14 mg; 100 mg/mL) added to the reaction mixture and left to react 
overnight. The reaction mixture was washed in DMF (2x) by centrifugation and resuspended in 
DMF (1 mg; 1 mg/mL). Post-PEGylation, the unreacted amine groups on the nanoparticle were 
quenched upon addition of pyridine (10 µL) and acetic anhydride (14 µL) and the mixture was 
shaken at room temperature for 30 minutes. The reaction mixture was washed in DMF (1x), pH 
9.5 borate buffer (1x), and sterile water (3x). Following surface modification of both 
nanoparticle types, the particles were analyzed by DLS, TGA, and SEM. 
3.4.5 Affibody Quantification 
For affibody quantification studies, the same conjugation methods were used for both 
PEGylation and acetylation procedures as described above. However, in place of the inert 
methoxy-terminated PEG5k-SCM, a maleimide-terminated PEG5k-SCM was conjugated in order 
to functionalize the cysteine-terminated Z
EGFR
 affibody to the NP surface. Following surface 
modification, the functionalized NPs were characterized by TGA and DLS analysis. After 
characterization, the NP suspension (1 mg) was centrifuged and swapped to a 20 mM HEPES / 
10 mM EDTA solution at ~1 mg/mL. Immobilized TCEP disulfide reducing gel (1.5x volume of 
affibody solution) was washed three times by spinning down the gel beads, removing the 
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supernatant, and resuspending in HEPES/EDTA solution (1 min; 600 rpm). FITC-labelled Z
EGFR 
affibody (0.5 mg/mL) modified with a non-structural terminal cysteine group was added to the 
pelleted TCEP gel and the slurry was mixed on a shaker plate (1200 rpm) at room temperature 
for 45 minutes. After disulfide reduction, the slurry was centrifuged (2 min; 600 rpm) and the 
affibody supernatant was removed from the reducing gel. The activated affibody was 
immediately added to the modified-nanoparticle solution (1 mg; 1 mL total volume) and shaken 
overnight (1400 rpm). The mass of affibody charged per mg of NPs varied depending on the 
nanoparticle type being functionalized (80 nm x 320 v. 55 x 60 nm). When modifying 80 x 320 
nm hydrogel particles, affibody was charged at 2.5, 5, 10, 25, or 50 µg per mg modified-NPs; 
however, with 55 x 60 nm NPs, affibody was charged at 10, 20, or 40 µg per mg NP. Thiol-
PEG1k-SH was dissolved in the HEPES buffer solution at 100 mg/mL and added (27 µL) to the 
NP reaction which continued to shake for three hours. The NP reaction was then centrifuged and 
washed in water (4x). The FITC-tagged affibody NPs were then characterized by DLS, SEM, 
and TGA.  
After conjugating fluorescently-tagged affibody to the nanoparticle surface, the amount 
of affibody conjugated to the particle was assessed by fluorescent analysis. The FITC tagged 
affibody-PEG-NP (1 mg/mL) solution was diluted 1:10 in borate buffer and transferred (200 µL) 
into a Corning black well plate in triplicate. The supernatant from the same nanoparticle solution 
was added to the black 96-well plate using the same method. A serial dilution of unconjugated 
FITC-affibody was utilized to create a standard curve (10 µg/mL - 0.01 µg/mL) and fluorescence 
measurements (λex = 494 nm; λem = 521 nm) of the 96-well plate containing the (1) targeted 
nanoparticle (2) standard curve (3) and supernatant were taken using a SpectraMax M5 plate-
reader. The fluorescence in the supernatant was subtracted from the fluorescence observed in the 
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nanoparticle suspension and the final fluorescence correlated to FITC-tagged affibody 
concentration via standard curve. 
3.4.6 Surface Conjugation of NPs for Targeted Studies 
For in vitro and in vivo studies with targeted nanoparticles, the conjugation methodology 
outlined above was followed. However, instead of FITC-labelled affibody, a non-tagged analog 
was used. A wild-type affibody was utilized as a negative control and it was conjugated to the 
functionalized NPs with identical methods. Additionally, a non-targeted PEG control was used as 
a second negative control and it was fabricated by following all steps outlined above except for 
the addition of targeting ligand. A completely non-functionalized positively charged particle was 
used as a positive control for in vitro experimentation.  
3.4.7 A431 Cell Association and Competition Assay 
For cellular association experiments, A431 cells were plated in complete medium 
(DMEM) at 20,000 cells per well in a 24-well plate and incubated overnight (37°C, 5% CO2) to 
50% confluence. Dye-labelled particles were then dosed at three different concentrations (5, 15, 
30 µg / mL) onto the A431 cells and incubated for 1 and 4 h. At these time points, cells were 
washed (3x) with 0.5 mL 1x PBS and the cells were detached from the plate with 1x 
trypsin/EDTA (300 µL / well). Cells were resuspended in 500 µL of a 0.2% TB solution (1:1 1x 
PBS with 10% FBS) for a total sample volume of 800 µL. The A431 cells were transferred to a 
polypropylene tube and analyzed using a flow. For each sample 10,000 cells were measured. 
3.4.8 Macrophage Association Study 
Murine alveolar macrophage cells (MH-S) were used to determine how nanoparticle 
association and internalization varies as a function of both targeting ligand density and 
nanoparticle size. In these studies, MH-S cells were plated (40,000 cells per well) in a 24-well 
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plate and incubated at 37°C for 48 h. Following the time period, dye-labelled (Dylight 488) 
nanoparticles (20 µg / mL) were incubated with the macrophage cells for 4 and 24 h. At the time 
points, cells were washed three times with 0.5 mL 1x PBS and 1x trypsin/EDTA (300 µL / well) 
was added to detach the cells from the plate. The cell solution was transferred to a polypropylene 
tube and analyzed using a flow cytometer. For each sample 10,000 cells were measured. 
3.4.9 In Vivo Studies 
All animal studies were carried out with the approved protocol by The University of 
North Carolina Animal Care and Use Committee. Female athymic nude mice (Foxn1
nu
; 20- 30 g) 
were dosed via tail vein injection from an 8 mg /mL nanoparticle suspension in an isotonic 9.25 
wt% sucrose solution.  
For all tumor studies, mice aged 4-6 weeks and 20-25 grams in body weight were 
purchased from UNC-Chapel Hill’s animal core. A431 cells were administered (2 x 106 cells in 
150 µL of DMEM) subcutaneously into the right rear flank of each mouse and tumor volume 
was estimated by the formula: mm
3
 = (w
2
 x l) / 2, where w = width and l = length of the tumor. 
After approximately 4 weeks, tumors were 300-500 mm
3
 and mice were randomized for each 
study arm.  
To determine nanoparticle size dependence on passive tumor accumulation, 
PEGylated/non-targeted hydrogels of two distinct sizes were dosed into tumor-bearing mice. 
Nanoparticle injections and harvesting of organs were performed with aid from the Animal 
Studies Core at UNC-Chapel Hill. Mice were dosed (60 mg / kg) with 80 x 320 nm particles, 55 
x 60 nm particles, or sucrose (N = 4 per arm). After 24 h, mice were anesthetized with a 
ketamine/ dexmedetomidine blend. Mice were then euthanized via cardiac puncture for blood 
collection (stored in heparinized Eppendorf tubes) and cervical dislocation for a secondary 
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conformation of death. Tissues were harvested (liver, spleen, lung, kidney, and tumor), weighed, 
and transferred to 12-well plates for fluorescence analysis on an IVIS Lumina instrument 
(Caliper Life Sciences) and fluorescence filters were set (λex = 675 nm / λem = 720 nm). 
Harvested blood (100 µL) from all samples was transferred into a black 96-well plate and a small 
aliquot of each particle type was pipette into blood from a control mouse (5 µL NP stock in 195 
µL blood) in order to normalize fluorescence between NPs.  
In an effort to determine how targeting ligand density affects blood retention over time, 
80 x 320 nm particles were administered and harvested at several time points. These studies were 
conducted with five different nanoparticle arms: 6.5 x10
-4
 LG/nm
2
, 1.8 x10
-3
 LG/nm
2
, 4.5 x10
-3
 
LG/nm
2
, PEG control, and a wild-type negative control (12.5 mg / kg). Mice were harvested at 
five different time points: 0.083, 0.5, 1, 3, and 24 h (N = 4 per time point for each NP arm). 
Tissue harvests and fluorescence analysis were both conducted in the same manner as methods 
previously described. PK analysis of blood retention studies were conducted with MS Excel PK 
Solver 2.0.
29
 Data was fit to a non-compartmental model for all nanoparticle type.  
Targeted tumor accumulation and biodistribution studies with targeted 80 x 320 nm 
hydrogels in A431 tumor-bearing mice were conducted as a function of targeting ligand density. 
The general procedure outlined in the non-targeted particle biodistribution section above was 
followed, except nanoparticle arms were altered. For this study, five different particles types 
were analyzed: 6.5 x10
-4
 LG/nm
2
, 1.1 x10
-3
 LG/nm
2
, 1.8 x10
-3
 LG/nm
2
, PEG control, and a wild-
type negative control (12.5 mg / kg). It should be noted that the NP ligand density at 4.5 x10
-3
 
LG/nm
2 
was not conducted due to poor blood retention observed in the previous pharmacokinetic 
experiment. Additionally, Dylight 650 was used as the nanoparticle imaging agent instead of 
Dylight 680.  
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In order to determine how NP size and targeting density affect tumor accumulation and 
biodistribution, in vivo trials were conducted with 55 x 60 nm particles in tumor-bearing mice. In 
this experiment five different nanoparticle arms were investigated: 1.2 x10
-3
 LG/nm
2
, 2.0 x10
-3 
LG/nm
2
, 3.0 x10
-3 
LG/nm
2
, PEG control, and negative control. Notably, ligand loadings were 
designed to closely match that of the 80 x 320 nm tumor accumulation study at the two highest 
ligand densities. As well, a third ligand density was appended onto the study to potentially 
enhance nanoparticle uptake in the tumor even further.  
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CHAPTER 4 MEDIATING PASSIVE ACCUMULATION WITH PRINT NANOPARTICLES: EFFECT OF 
PARTICLE SIZE AND TUMOR MODEL 
4.1 Introduction 
The fundamentals of particle delivery center around two unique parameters of solid tumor 
vasculature: tortuous and hyper-vasculature circulatory networks allowing macromolecular 
accumulation and poor lymphatic filtration allowing the carrier to persist within the tumor, 
notably termed the Enhanced Permeation and Retention (EPR) Effect.
1,2,15
 While hypothesized in 
the 1980’s, the academic endeavors are only recently transitioning to clinical benefit and 
realistically the overall value to this point has been marginal.
3-5
 The central roadblock to 
translational success is not unique to particulates, but, an overarching issue with all novel 
treatments against disease: the necessity of predictive pre-clinical models. In the case of cancer, 
recapitulation of human disease is hindered by intrinsic complexity of the diseased tissue due to 
the heterogeneity in even a single cancerous mass.
6,7 
 Similar to normal homogeneous tissue, cancerous tissue requires a blood vessel network 
that supplies sufficient nutrients, effectively clears waste, and transports oxygen within 100 – 
200 μm of growing tissue, a length well within the confines of diffusion.6,8 However, unlike 
healthy tissue, diseased and rapidly proliferating tissue undergoes angiogenesis uncontrollably 
when angiogenic activators (VEGF family, TGF-β receptors, PECAM, etc.) are upregulated over 
angiogenic inhibitors (VEGFR-1, endostatin, vasostatin, etc.) yielding non-uniform and chaotic 
vasculature that varies drastically over the entire tumor mass; yet, extent of this heterogeneity 
has been shown to depend on the unique properties of the specific cancer: tumor type, location, 
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and mass size.
3,8-13
 Simultaneously, these attributes affect the extent of EPR that a solid tumor 
mass presents, leading to major differences in macromolecular accumulation. 
The degree of EPR has shown to fluctuate drastically with unique properties of the specific 
cancer. Along with differences in blood vasculature, the amount of connective tissue (stroma), 
presence of a lymphatic network, and level of interstitial pressure has all shown to differ among 
individual cancers.
14-18
 These characteristics impact how appropriate a nano-formulation is for a 
particular cancer type over more traditional small molecule therapy. For instance, pancreatic 
cancer typically expresses high amounts of stroma, is poorly vascularized, and lacks significant 
lymphatic drainage.
19,20
 While poor lymphatic drainage is beneficial for particle retention, 
negligible vascularization and extraordinary presence of connective tissue make particulate 
deposition unlikely. The activity of the mononuclear phagocyte system (MPS) has also shown to 
fluctuate from cancer to cancer, yielding vastly different particle clearance, affecting blood PK, 
and overall influencing particle accumulation.
21,22
 Finally, fenestrations in the tumor vasculature 
into and within the diseased mass differs greatly, so, an optimal NP diameter may exist that 
penetrates most effectively throughout the solid tumor.
5,23-25
 In general, a consensus in literature 
exists that decreasing carrier size will improve tumor deposition.
 11,12,25,28-30
 
While reducing particle size is generally considered advantageous, tumor deposition and 
overall performance of the carrier varies throughout literature due to the heterogeneity of 
nanoparticle systems and disease models.
11,12,25,28-30
 In a specific instance, a series of Pt-loaded 
polymeric micelles (30, 50, 70, and 100 nm) were observed to accumulate equivalently in a 
highly-permeable subcutaneous murine colon adenocarcinoma model resulting in comparable 
inhibition of tumor growth. However, the same NP set was tested against a hypopermeable 
subcutaneous human pancreatic adenocarcinoma model and vastly different accumulation among 
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the NP sizes was observed. In the poorly vascularized pancreatic model, the two smaller NPs 
accumulated 2 – 3 times greater than the larger two NPs resulting in vastly improved tumor 
inhibition for the smaller NPs.
13
 In a different research group, gold NPs (AuNPs) were 
investigated (20, 40, 60, 80, and 100 nm) within a hypervascularized subcutaneous human breast 
melanoma model resulting in tumor accumulation irrelevant of size, but, dictated by particle 
half-life in the blood.
26
 In a separate research group, an orthotopic model was developed from 
the same MDA-MB-435 cell line and a series of AuNPs (15, 30, 60, and 100 nm) were once 
again studied. In this case, AuNPs were observed to accumulate within the diseased tissue in 
accordance with particle size, with smaller AuNPs leading to enhanced deposition.
27
 In these 
accounts, tumor sequestration was observed to change with cancer type (pancreatic vs. colon vs. 
breast), model (subcutaneous vs. orthotopic), and in some cases, particle size. The complicated 
nature of particle tumor deposition highlights just how imperative it is to exhaustively evaluate a 
carrier. 
To this aim, we investigated the effects of nanoparticle size/shape, cancer cell type, and 
disease model type in vitro and in vivo. Utilizing PRINT, nanoparticles were manufactured in 
three distinct sizes: 55 nm x 60 nm, 80 nm x 80 nm x 180 nm, and 80 nm x 80 nm x 320 nm and 
all were densely PEGylated post-fabrication. In vitro, there was no discernable difference in 
cellular interaction between the nanoparticle types. In vivo, biodistribution and blood 
pharmacokinetic profile were statistically similar among all three NPs in healthy nude mice. 
Administration of PRINT NPs into four different subcutaneous tumor models showed 
dramatically different tumor accumulation between the different cancer cell types with evident 
particle size dependence. Immunohistochemistry (IHC) staining revealed distinct microvessel 
densities among the four subcutaneous tumors sectioned which seemed to correspond with 
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overall tumor deposition. Finally, an orthotopic model was tested with three of the cancer cell 
lines revealing preferential accumulation in primary tumors and metastases over healthy tissue. 
Overall, tumor accumulation was observed to vary dramatically with particle size, cancer cell 
line, and disease model. 
4.2 Results and Discussion  
4.2.1 Particle Fabrication and Characterization 
The fabrication and characterization of hydrogel nanoparticles of sizes 80 nm x 80 nm x 
320 nm and 55 nm x 60 nm is identical to details in sections 3.4.2 and 3.4.3. The 80 nm x 80 nm 
x 180 nm NP was fabricated utilizing the same protocol as the 80 nm x 80 nm x 320 nm particle. 
In this account, however, isopropanol (instead of methanol) was utilized in all pre-particle 
solutions as it provided a more uniform thin polymer film. Previously, when using methanol as a 
solvent, stringent climate control was essential for successful particle fabrication. In previous 
accounts of fabrication, temperature ranges of approximately 60 – 70 °F and humidity between 
10 – 30 % RH were required. Under current procedures utilizing isopropanol, distinct control 
over temperature and humidity is not necessary assuming typical environmental working 
conditions (temperature 70-75°F; humidity 10-50% RH). A simple change in pre-particle solvent 
has given the DeSimone group a more robust fabrication technique that yields an array of diverse 
nanoparticle types (Figure 4.1and Table 4.1).  
 
Figure 4.1 Scanning electron micrographs of 55 x 60 nm, 80 x 180 nm, and 80 x 320 nm PRINT hydrogel particles. 
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Table 4.1 Particle characterization by dynamic light scattering 
4.2.2 Biodistribution and Blood Pharmacokinetics in Healthy Mice 
Extending circulation time of nano-based drug delivery systems upon I.V. administration 
is an important factor facilitating accumulation in cancerous tissue.
26,31
 By improving I.V. blood 
retention, particulate drug systems have a greater probability of permeating into the porous and 
hyper-vascularized neoplastic tissue. In previous accounts, nanoparticle size has been closely 
attributed to unique blood pharmacokinetic profiles with smaller particulates extending blood 
retention.
32,33
 In addition, particle size is widely-noted as the most dominant parameter 
improving solid tumor uptake with decreasing NP size.
11,12,25,28-30 
The intertwined relationship of 
nanoparticle size, blood PK, and tumor accumulation clouds what exact factors lead to improved 
tumor delivery and due to this complicated relationship, we wanted to conduct blood 
pharmacokinetic studies in Foxn1
nu
 mice with PRINT NPs of three distinct sizes: 80 x 320, 80 x 
180, and 55 x 60 nm. In all in vivo and in vitro studies, particles were surface-modified with a 
dense coating of methoxy-terminated poly (ethylene glycol) that has shown to dramatically 
enhance circulation time as noted in Chapter 2.
34
 Interestingly, blood pharmacokinetic profiles of 
the three NP types displayed no statistically significant difference in PK behavior (Figure 4.2). 
Key pharmacokinetic parameters for different NP sizes such as circulation half-life (t1/2 β), 
volume of distribution (Vd), and area-under-curve (AUC) all fell within statistically similar 
values of approximately 13-20 hours, ~1.3 mL, and 15 mg/mL·h, respectively (Table 4.2). These 
NP Type 
(nm) 
Z-avg 
(nm) 
PdI 
ZP 
(mV) 
55 x 60 126 ± 4 0.09 ± 0.01 -19 ± 1 
80 x 180 184 ± 4 0.07 ± 0.01 -20 ± 1 
80 x 320 257 ± 5 0.01 ± 0.01 -23 ± 1 
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results may indicate that any differences in tumor accumulation can be attributed to size and not 
a different pharmacokinetic behavior. Biodistribution upon organ resection revealed similar 
deposition between main tissues for nanoparticle clearance for all NP types (Figure 4.3) with 
slight dependence on NP size observed within the kidneys. 
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Figure 4.2 Blood pharmacokinetics of three NP types in healthy mice at serveral time points: 0.5, 4, 24, 48, and 72 h 
(n = 5 per NP arm). 
 
Table 4.2 Blood pharmacokinetics as a function a nanoparticle type 
 
55 x 60 80 x 180 80 x 320 
t1/2 α 
(h) 
4.0 ± 4.4 7.7 ± 3.1 4.5 ± 1.9 
t1/2 β 
(h) 
12.8 ± 1.4 14.7 ± 2.9 20.3 ± 7.3 
Vd 
(mL) 
1.4 ± 0.1 1.3 ± 0.1 1.3 ± 0.2 
CL 
(mL/h) 
0.08 ± 0.01 0.09 ± 0.02 0.08 ± 0.01 
AUC0-t 
(mg/mL·h) 
15.4 ± 1.9 14.3 ± 3.0 14.6 ± 1.3 
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Figure 4.3 Biodistribution of 55 x 60, 80 x 180, and 80 x 320 nm in healthy mice at 24 hour post-injection at 60 mg / 
kg (n = 4). 
4.2.3 In Vitro Assessment of NPs 
While blood pharmacokinetic profile and biodistribution of the three different PRINT 
hydrogels were similar, it was of interest to validate in vitro behavior. The DeSimone lab has 
previously shown major differences in cellular interactions based nanoparticle shape. In these 
accounts, high aspect ratio nanoparticles were shown to internalize at a faster rate in HeLa cells, 
yet, it is of significance to note said particles exhibited a strong positive charge facilitating this 
interaction.
35
 In current studies, the densely PEGylated nanoparticles exhibited a negative 
surface charge as previously shown in Table 4.1 and all nanoparticle sizes poorly associated with 
the cancer cell lines of interest (Figure 4.4) after a 24 h incubation period. As expected, 
phagocytic alveolar murine macrophage associated with all three nanoparticles types at 
approximately 20-30 % association after 24 h which is similar to previously described findings 
(See Figure 2.5). Overall, the PEG-coating paired with the negative surface charge of the various 
NPs seemed to effectively shield interaction with non-phagocytic cancer cells no matter the 
particle shape. 
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Figure 4.4 In vitro cell association of various NP types with murine macrophages (MH-S) and three different cancer 
cell types (A431, A549, and SKOV-3). 
4.2.4 NP Distribution in Flank Tumor Models and Immunohistochemistry  
Pre-clinical animal models that accurately predict behavior in a clinical setting is perhaps 
the greatest current challenge in drug development.
3,36
 Improper or incomplete validation of 
nano-based drug delivery methods by non-predictive animal models and inappropriate 
assessment of success pre-clinically can be tied to wasted endeavors in early clinical 
development.
36,37
 Needless to state, it is of dire circumstance that a nanotherapy is exhaustively 
validated in a number of disease models prior to adorning it efficacious. In an effort to validate 
the impact of various PRINT NPs towards solid tumor delivery, we analyzed accumulation in 
several murine flank tumor models. While flank tumor models are hardly predictive in nature, 
they are frequently used in nanoparticle drug delivery literature to test how well the carrier 
deposits within solid tumor tissues. The aim of these studies was to determine how tumor 
accumulation varied across different flank tumor models and then determine how these findings 
translated to more predictive orthotopic cancer models.  
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Mice were injected subcutaneously in the right flank with either A549 (human non-small 
cell lung cancer cells), A431 (human epidermoid cancer cells), SKOV3 (human ovarian cancer 
cells) or 344SQ (mouse non-small cell lung cancer cells). When flank tumors reached ~ 100 mm
3
, 
mice were injected (tail vein) with either 80 nm x 320 nm, 80 nm x 180 nm, or 55 nm x 60 nm 
PRINT particles. Particle biodistribution was assessed 24 hours post NP injections via organ 
resection and fluorescent imaging. Upon fluorescence analysis, it was evident that both 
nanoparticle size and disease type/model had drastic effects on overall accumulation in the solid 
flank tumors (Figure 4.5). The 55 x 60 nm particle out performed all particle types in the A431, 
SKOV3, and 344SQ flank tumor models. Interestingly, in the A549 flank tumor model, the 55 
nm x 60 nm and the 80 nm x 180 nm particles performed statistically the same. In most cases, a 
positive correlation existed between reductions in NP size and flank accumulation; however, it is 
currently unknown whether pore cutoff size in the tumor vasculature is the main driver of this 
observation. In three of four flank models (SKOV3, A431, and A549) tumor deposition ranged 
from ~3-15% depending on the NP type, yet, the 344SQ tumor model yielded significantly 
increased deposition between ~15%-38%. Biodistribution in flank tumor-bearing mice displayed 
similar distributions throughout the four models with slight variations in spleen and liver 
delivery (Figure 4.6). It is reasonable to assume that alterations in biodistribution between model 
types can at least in part be attributed to differences in tumor depot as biodistribution in healthy 
mice was statistically similar.  
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Figure 4.5 Flank tumor accumulation of PRINT particles of various sizes and shapes was evaluated at 24 h post-
injection at 60 mg/kg. Data displayed as percent recovered fluorescence per gram of tissue (n = 4). 
 
 
Figure 4.6 Biodistribution of NPs at three distinct sizes in four different tumor-bearing mouse models at 24 h post-
injection (60 mg / kg). Organs of interest were resected and fluorescently imaged (n = 4). 
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 Upon resection of flank tumors and fluorescent imaging, visual differences were noted 
and immunohistochemistry was conducted to determine variance in cell surface markers and 
tumor vascularization. Upon visual inspection, A431 flank tumors seemed to be more 
vascularized than the A549 and SKOV-3 tumor tissues (Figure 4.7). Upon fixation, sectioning, 
and staining the microvessel density, as identified with a CD-31 endothelial cell marker, seemed 
to vary across the different flank tumors 344SQ > SKOV3> A431> A549 (Figure 4.8). This 
finding was corroborated with complete vessel, endothelial vasculature coupled with lumen, in 
the same manner. Interestingly, the microvessel density seemed to align well with overall flank 
tumor deposition of NPs. Lymphatic tissue (Lyve1), tumor-associated macrophage (TAMs; 
F4/80), collagen (Collagen IV), and vascular endothelial growth factor (VEGF) markers were 
also utilized during IHC staining (Figure 4.9). The highest expression of collagen and TAMs 
were observed with the 344SQ and A549 cell lines while lymphatic tissue and VEGF seemed 
equivalent across all sections. In previous accounts, high collagen expression is associated with 
poor tissue vascularization which in thought would lead to low NP tumor deposition.
38
 In this 
account, however, both microvessel density and collagen expression are the highest for the 
344SQ flank model which displayed the highest NP tumor depot. While it is not clear at this time 
what accounts for this discrepancy, there seems to be a stark difference in microvessel density, 
collagen, and TAMs across the different flank models. 
 
Figure 4.7 Photographs of different flank tumors once resected from the mouse. 
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Figure 4.8 Immunohistochemistry analysis of parafilm-fixed flank tumors. Vascularization of the cancerous tissue 
was identified with a CD-31 marker. Complete vessel is defined as endothelial tissue coupled with lumen. 
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Figure 4.9 Immunohistochemistry analysis of parafilm-fixed flank tumors with several markers: lymphatic vessel 
(Lyve1), tumor-associated macrophage (F480), collagen (Collagen IV), and vascular endothelial growth factor 
(VEGF). 
4.2.5 NP Distribution in Orthotopic Tumor Models 
Assessment of drug or drug carrier performance in clinically relevant pre-clinical models 
is imperative to ascertain potential success. While there are obvious limitations translating 
discoveries from mice to humans, there are certain mouse models that better reflect human 
cancer pathology.
39,40
 In line with this, it should be noted that while enhanced deposition of a 
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carrier to a flank tumor may reflect potential benefits in drug delivery, the clinical course of 
action for a large solid mass would traditionally be surgery followed by radiation/chemo therapy. 
In light of this, nanoparticle therapies may be better suited to aid in cancer treatment if they 
could preferentially target metastatic disease over healthy tissue. To this aim, particle deposition 
into three different metastatic orthotopic mouse models was investigated: 344SQ (lung), A549 
(lung), and SKOV3 (ovarian).  
The deposition of 55 x 60 nm PRINT NPs was assessed in three different orthotopic 
mouse models that were also prone to metastatic growth. In these studies, a preferential 
deposition of the hydrogel carrier was observed in the primary tumor and metastatic tissue over 
healthy tissue. In the A549 lung model, disease was apparent at the primary injection site post-
surgery along with significant lymphatic disease. In the 344SQ lung model, disease was 
observed in the lung tissue and several metastases formed in the lymph nodes, pleural cavity, and 
along the chest wall (Figure 4.10 and Figure 4.13). Fluorescent images from the primary lung 
tumors display, in a compelling fashion, dramatic particle accumulation in the diseased sites in 
comparison to surrounding healthy lung tissue. The ovarian model displayed significant disease 
in the intraperitoneal cavity along with metastases in the liver (Figure 4.11). As seen in Figure 
4.12, particle distribution in the three orthotopic models does not necessarily reflect what was 
previously observed in the flank models, most notably the drastic variance between the A549 
cell-line. As well, it was surprising that particle accumulation in the diseased tissue was so high, 
ranging from 20 – 50% (Figure 4.12 D). In general, particle distribution was observed in all 
metastatic disease throughout each model albeit at different extents (Figure 4.13). The 
establishment of more clinically relevant mouse models along with the preferential delivery of a 
particle carrier bodes well for the use of PRINT in a clinical setting. Nevertheless, only with the 
 94 
incorporation of chemotherapeutic and subsequent advancements in efficacy of that therapeutic 
can we establish the success of this carrier.  
 
Figure 4.10 Photograph and fluorescence images of orthotopic 344SQ (left two) and A549 (right two) tumors treated 
with fluorescently labeled PRINT particles indicating preferential accumulation of particles in diseased tissue. White 
trangles indicate primary tumors, and blue triangles indicate either lymph node metastasis or pleural cavity tumors. 
 
 
 
Figure 4.11 Representative photograph of orthotopic SKOV-3 tumors (indicated by the white triangle) formed in the 
IP cavity of a nude mouse. 
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Figure 4.12 Biodistribution of 55 x 60 nm particles in tumor-bearing mice 24 h post-injection (60 mg / kg). Organs 
of interest were resected and imaged via fluorescence. Both orthotopic (gray bar) and flank (black bar) tumor 
models were investigated for the following cell lines (A) 344SQ, (B) A549, (C) SKOV3. Total fluoresence of 
diseased tissue was compared in orthotopic models (D). 
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Figure 4.13 Biodistribution of 55 x 60 nm particles in metastatic disease sites throughout the three orthotopic mouse 
models: A549 (top-left), SKOV-3 (top-right), and 344SQ (bottom). 
4.3 Conclusions 
In this account, we utilized PRINT to manufacture hydrogel particles of various 
sizes/shapes to examine how NP size, tumor cell-line, and tumor location affect particle 
sequestration in cancerous tissue. The three different particle types: 80 nm x 80 nm x 320 nm, 80 
nm x 80 nm x 180 nm, and 55 x 60 nm were surface-modified with a dense brush of 
poly(ethylene glycol) and exhibited a negative surface charge which in tandem has shown to 
dramatically enhance blood retention, macrophage resistance, and protein resistance. Unlike 
previous accounts, the various particle sizes exhibited similar blood pharmacokinetic behavior, 
association with cancerous cells, and resistance to macrophage uptake. Four flank tumor mouse 
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models were tested for particulate accumulation revealing vastly different deposition among the 
different particle types and models. The IHC staining displayed stark differences in the different 
flank models with microvessel density, collagen, and TAMs varying among the solid tumors. 
Upon administration of the 55 nm x 60 nm particle into orthotopic tumor models, significant 
accumulation was observed in both primary and metastatic sites. While preferential metastatic 
accumulation of PRINT nanoparticles is encouraging, we will not know the true impact until a 
potent chemotherapeutic is incorporated and efficacy studies are carried out in a number of 
clinically translatable models. 
4.4 Materials and Methods 
4.4.1 Materials 
2-aminoethyl methacrylate hydrochloride (AEM), diphenyl (2,4,6-trimethylbenzoyl) 
phosphine oxide (TPO), poly (ethylene glycol) diacrylate (Mn 700) (PEG700DA), trypsin, 
ethylenediaminetetraacetic acid (EDTA), and sucrose were obtained from Sigma-Aldrich. 
Thermo Scientific Dylight 488, 650, and 680, Thermo Scientific HyClone fetal bovine serum 
(FBS), triethylamine (TEA), acetic anhydride, isopropanol, sterile water, dimethylformamide 
(DMF), Dulbecco’s phosphate buffered saline (pH 7.4) (DPBS), 1X phosphate buffered saline 
(pH 7.4) (PBS), and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from Fisher 
Scientific. Methoxy-PEG5k- succinimidyl carboxy methyl ester (mPEG5k-SCM) was obtained 
from Creative PEGWorks (Winston Salem, NC). Polyvinyl alcohol (Mw 2000) (PVOH) was 
bought from Acros Organics. Murine alveolar macrophage (MH-S), human epidermoid 
carcinoma (A431), and human ovarian adenocarcinoma (SKOV3) cells were purchased from 
American Type Culture Collection. Murine lung adenocarcinoma (344 SQ) and human non-
small cell lung carcinoma (A549) were graciously provided by the laboratories of Dr. Chad 
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Pecot. PRINT molds (80 nm x 80 x 320 nm, 80 nm x 80 nm x 180 nm, and 55 x 60 nm) were all 
acquired from Liquidia Technologies. As described in previous accounts, tetraethylene glycol 
monoacrylate (HP4A) was synthesized in-house. 
41
 For all immunohistochemistry and staining, 
rabbit polyclonal antibodies against CD31 (ab28364) and Lyve1 (ab14917) were from Abcam 
(Cambridge, MA), Collagen IV (AB8201) form EMD Millipore (Billerica, MA), and VEGF (sc-
152) from Santa Cruz Biotechnology (Dallas, Texas). Rat monoclonal antibody F4/80 (clone 
BM8, # 14-4801-82) was from eBioscience Inc. (San Diego, CA). 
4.4.2 Nanoparticle Fabrication 
The fabrication of 55 x 60 nm and 80 x 320 nm PRINT nanoparticles was fairly similar to 
previous methods as described in sections 2.4.2 and 3.4.2. Instead of methanol as the pre-particle 
solvent, isopropanol was utilized in effort to create a polymer film less dependent on temperature 
and humidity conditions. For the 80 x 80 x 180 nm particle, a Teflon-like PRINT mold (as 
provided by © Liquidia Technologies) was utilized and the fabrication procedure was equivalent 
to the 80 x 320 nm NP type. In addition, purification procedures for the 80 x 320 nm and 55 x 60 
nm types were kept consistent to previous descriptions and only alteration for the 80 x 180 nm 
type was the centrifuge time (45 – 90 minutes). 
4.4.3 Nanoparticle Characterization 
The nanoparticles were characterized by dynamic light scattering, thermal gravimetric 
analysis, and atomic force microscopy as previously described in sections 2.4.3 and 3.4.3. 
However, minor alterations were made to the scanning electron microscopy imaging protocol. 
The microscopy sample preparation was changed to reduce swelling of the hydrogel matrix prior 
to SEM analysis resulting in vastly improved images. Before SEM analysis, a particle solution in 
N,N-dimethylformamide was diluted further in DMF to 50 µg/mL and 1 µL of that solution was 
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pipette onto a clean silicon wafer. The solvent was allowed to evaporate from the wafer 
overnight and dried further with a heat gun. The sample was allowed to cool to room temperature 
and imaged immediately thereafter. 
4.4.4 Surface Modification for In Vitro and In Vivo Experiments 
After the nanoparticles were purified in sterile water, the suspension was washed into 
DMF (3x) using the centrifugation method (14,000 RPM; 0.5 to 3 h). In effort synthesize NPs for 
large-scale in vivo studies, modification procedures were effectively scaled-up by five-fold.  The 
concentration was assessed by TGA and the particles were concentrated (5 mg / mL). The 
particle solution (5 mg; 4.3 mg/mL) was reacted with TEA (100 µL), methoxy-PEG5k-SCM (140 
µL; 100 mg / mL in DMF), and left to react overnight. The reaction mixture was washed once in 
DMF and unreacted amines were quenched with addition of pyridine (50 µL), acetic anhydride 
(70 µL), and shaken at room temperature for 30 minutes. The mixture was washed once in DMF, 
once in pH 9.5 borate buffer, and sterile water (3x). Following surface modification of all three 
nanoparticle types, the particles were fully characterized by methods previously described. 
4.4.5 Cellular Association Studies 
Cell association studies were conducted with identical procedures for each individual cell 
type as outlined in sections 3.4.7 and 3.4.8. In these experiments three distinct particle sizes were 
tested against four different cell lines: murine alveolar macrophage (MH-S), human non-small 
cell lung carcinoma (A549), human ovarian adenocarcinoma (SKOV-3), and human epidermoid 
carcinoma (A431). As noted before, cell association was assessed via FACS analysis.  
4.4.6 In Vivo Studies 
All animal studies were carried out with the approved protocol by The University of 
North Carolina Animal Care and Use Committee. In all mouse models, female athymic nudes 
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(Foxn1
nu
; 20- 30 g) were dosed with a 60 mg / kg tail vein injection from an 8 mg /mL 
nanoparticle suspension in a 9.25 wt% sucrose solution. 
PRINT NPs of three distinct sizes were administered into healthy female mice in effort to 
determine how nanoparticle size alters biodistribution and blood pharmacokinetics. For these 
studies, surface-modified 55 x 60, 80 x 180, and 80 x 320 nm NPs were injected via tail-vein (n 
= 5 per NP arm). At each time point (0.5, 4, 24, 48, and 72 h), whole blood (20-30 µL per time 
point) was collected via tail nick directly into a heparinized Eppendorf tube and stored at 4°C 
until the final time point was collected. At 72 hours, mice were euthanized and sacrificed via 
cardiac-puncture and cervical dislocation. Organs of interest were collected (spleen, liver, lungs, 
kidneys) and blood from the cardiac puncture was utilized as the last blood PK time point. 
Whole blood (15 µL) from all time points was diluted into sterile water (135 µL), thoroughly 
shaken, and 100 µL was pipette into an opaque 96-well plate. A standard curve was created by 
diluting a small aliquot (10 µL) of each NP type into freshly harvested blood from control mice 
(n = 3 per NP arm) in order to normalize the fluorescence between NPs. Fluorescence 
measurements were taken from organs and blood as previously described in sections 2.4.9 and 
3.4.9. In these studies, PK Solver 2.0 was utilized to determine important pharmacokinetic 
parameters as in section 3.4.9. 
For flank tumor studies, mice were aged 6 – 8 weeks and injected in the right rear flank 
with tumor cells. Mice were inoculated with one of four cell lines: 5 x 10
6 
SKOV3 cells in 1X 
PBS, 5 x 10
6
 A549 cells in 1 x PBS, 2 x 10
6
 A431 cells in DMEM, or 1 x 10
5
 344SQ cells in 1 x 
PBS. Tumor growth was measured twice weekly via caliper measurements. When tumors 
reached ~150 mm
3
 mice were injected with one of three NP types and 24 hours later mice were 
sacrificed, harvested, and fluorescently imaged. For greater detail of flank tumor biodistribution 
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studies reference sections 2.4.9 and 3.4.9. For orthotopic tumor studies, lung cancer cells were 
implanted via intra-thoracic injection into either female nude (A549 cells) or female SvJ mice 
(344SQ cells) at six weeks of age. Mice were inoculated with either 1 x 10
6
 A549 cells or 1 x 10
5
 
344SQ cells (1:1 ratio of Hank’s media and BD Matrigel) and disease progression was monitored 
by weight gain/loss and overall health of mouse. Luciferase-expressing SKOV3 cells (1x 10
6
) 
were resuspended in 200 µL 1X PBS and injected with a 25 gauge needle IP into female nude 
mice and disease progression was monitored by bioluminescence. At 4 weeks post-inoculation 
(lung cancer models) and 13 weeks (ovarian cancer model), mice were dosed with fluorescently-
labeled 55 x 70 nm particles. Mice were once again euthanized, sacrificed/harvested, and imaged 
at 24 hours with methods previously noted.  
4.4.7 Immunohistochemistry Analysis 
Flank tumors were harvested from mice once they reached 150 mm
3
; they were fixed in 
formalin and processed by the University of North Carolina’s Translational Pathology 
Laboratory (TPL). Immunohistochemistry analysis was carried in the Bond fully-automated slide 
staining system (Leica Bicrosystems Inc. Vist, CA). Slides were deparaffinized in Bond dewax 
solution (AR9222) and hydrated in Bond wash solution (AR9590). Antigen retrieval was 
performed at 100°C in Bond-epitope retrieval solution 1 [pH-6.0] (AR9961) for Collagen IV and 
F4/8 (20 minutes), VEGF and Lyve1and CD31 (30 minutes). Bond-epitope retrieval solution 
1(20 min) or Bond enzyme 1 (5 min, AR9551) for F4/80. After pretreatment, CD-31 (1:50), 
VEGF (1:100), F4/80 (1:50), Lyve1 were applied for 1 h and Collagen IV for 30 min. Detection 
of F4/80 was performed using Bond Intense R Detection System (DS9263) supplemented with 
the biotinylated goat anti-Rat IgG (ab7096, Abcam). The rest of were supplemented with Bond 
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polymer refine detection system (DS9800). Stained slides were dehydrated and cover-slipped. 
Positive and negative controls (no primary antibody) were included for each antibody. 
Sections were digitally imaged (20X objective) in the Aperio ScanScope XT using line-
scan camera technology (Leica Biosystems). Digital images were stored and analyzed with 
Aperio eSlide Manager Software. Tumor areas were circled on each slide using Aperio positive 
pen tool. Tumor identification was guided by H&E slide. Collagen IV and VEGF signal was 
quantified using Aperio color deconvolution algorithm version 9. This algorithm calculates the 
area and intensity for the positive stain and generates Score (0-300). Aperio membrane v9 
algorithm was used for F4/80 and Lyve1 positive cells, and microvessel v1 for CD31. These 
procedures were kindly provided by Nana Feinberg of TPL. 
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CHAPTER 5 ENVIRONMENT-SENSITIVE DRUG RELEASE FROM PRINT NANOPARTICLES 
5.1 Introduction 
As discussed in Chapters 2, 3, and 4 the basic PRINT hydrogel nanoparticle formulation 
has been vastly improved for both passive and active targeting of diseased tissue. Optimization 
of the NP surface chemistry with either inert poly (ethylene glycol) or active Z
EGFR
 targeting 
affibody has enhanced the carrier’s in vivo behavior.1 Furthermore, a reduction in NP size 
improved tumor deposition immensely in a number of murine disease models and preferential 
accumulation was observed at the target cancer site. With these improvements in the carrier and 
identification of disease models most appropriate for a nanoparticle therapy, our current 
endeavors focus on the incorporation of a potent chemotherapeutic into the particle matrix. In 
this work, incorporation of gemcitabine pro-drugs for site-specific release in the tumor bed is the 
main emphasis. 
Pro-drug techniques are utilized throughout literature as an effective way to deliver toxic 
payload specifically to the target site while bypassing healthy tissue. In some cases, “pro-drug” 
indicates the API must be activated by a chemical, enzymatic, or biological mechanism in vivo 
prior to evoking a toxic effect, as in the case of gemcitabine. Gemcitabine must first influx into 
the cell by means of nucleoside transporters and intracellularly convert to diphosphate and 
triphosphate analogues that are responsible for its cytotoxicity.
18
 In the case of quercetin, a 
potent tyrosine kinase inhibitor, no oral bioavailability was expressed and was therefore altered 
with a carboxyl-functionality to enhance solubility upon IV-administration. After IV-treatment, 
 107 
the pro-drug hydrolyzed and converted back into its active analogue.
19
 As indicated, pro-drug 
formulations have been utilized to overcome issues with drug activity and delivery, as well as, 
several other issues in therapeutic administration.
20,21
 
In the case of nanoparticulate delivery, pro-drug formulations can be utilized as a way to 
complex or covalently bind the API to the carrier. In some instances, the API can be complexed 
into a polymeric backbone and subsequently assembled into a micelle, as well, direct 
encapsulation and surface complexation of the drug are common.
22-25
 These methods often 
require external stimuli, such as near-IR light, or internal stimuli, such as innate salt content in 
plasma, to convert Pt (IV) to cytotoxic Pt (II) complexes.
24,25 
These stimuli-dependent linkages 
can prove to be advantageous when trying to limit off-target sequestration of the toxic payload. 
As well, these linkages can promote drug release specifically at the desired disease site. 
In the laboratories of Dr. Joseph M. DeSimone, a number of pro-drug PRINT systems 
have been developed that incorporate potent therapeutics.
2-8
 In one account, docetaxel was 
successfully encapsulated within a PLGA carrier and upon administration in vivo improved 
plasma pharmacokinetics, drug biodistribution, and tumor regression was observed.
3
 In order to 
overcome the burst release commonly observed with drug encapsulation into a thermoplastic 
PLGA matrix, docetaxel was lipidized through a pH-sensitive linkage. In this case, the lipidated 
pro-drug diffused much slower through the hydrophobic PLGA matrix leading to sustained 
release at physiological conditions and dramatically improved tumor regression when compared 
to the free-drug and non-lipidated analogs.
4
 Along with drug encapsulation into a PLGA matrix, 
the DeSimone lab has developed therapeutic systems amenable for direct functionalization into 
hydrophilic thermoset. 
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In order to chemically attach a chemotherapeutic throughout an acrylic thermoset, the 
drug must be modified with a chemical entity amendable to radical polymerization. In the 
DeSimone lab, a number of common chemotherapeutics have been modified with this acrylate 
functionality through a pH-sensitive silyl ether linkage and the steric nature of the silanol 
substituent groups were modified to greatly reduce susceptibility of acidic or basic hydrolysis.
9
 
With this pH-sensitive linkage, drug release at physiological conditions (pH~7.4) was 
diminished. Subsequently, if the carrier were administered in vivo, it could accumulate in the 
diseased tissue with the majority of toxic payload still loaded. Once at the target site, the carrier 
can be internalized within the cell by one of the reported mechanisms of particulate endocytosis 
and upon reaching the acidic environment of the late-endosome the toxic payload can be released, 
killing the diseased cell. Deviating from pH-dependent drug release, another site-specific release 
system was developed in house that utilizes differences in reduction potential within subcellular 
compartments.  
Covalent disulphide linkages are susceptible to thiol- reduction when in the presence of 
molecules that express free thiol functionality. Glutathione is one such molecule found in vivo 
that expresses a free thiol, furthermore, the molecule is found at exceedingly high concentrations 
(1-10 mM) in the cytoplasm, as opposed to normal extracellular concentrations of 1-10 µM.
10,11 
Similar to previously discussed pH-dependent linkage, the DeSimone group capitalized on this 
concentration disparity and synthesized a model siRNA therapeutic with acrylate functionality 
through a reversible disulphide linkage.
6,12
 With this reducible linkage, a high loading of active 
therapeutic entrapped within the particle matrix and upon dosage to HeLa cells, significant gene 
knockdown was observed.
12
 Recently, this disulphide linkage has been repurposed for 
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conjugation with gemcitabine, a common nucleoside metabolic inhibitor, indicated for breast, 
ovarian, non-small cell lung, and pancreatic cancers.
13,14 
To this aim, we fabricated two 80 nm x 80 nm x 320 nm PRINT particles with either a 
pH-dependent gemcitabine pro-drug or an intracellular reducing-dependent gemcitabine pro-drug. 
The total drug-loading and time-dependent release of these nano-carriers via drug dissolution and 
HPLC analysis revealed vastly different release kinetics between the two linkages. The 80 nm x 
80 nm x 320 nm NPs with reducible pro-drug were dosed onto three separate cancer cell-lines 
revealing potent cytotoxic effect. In future studies, the reducible pro-drug will be tested in vivo 
for therapeutic effect. 
5.2 Results and Discussion 
5.2.1 Pro-drug Nanoparticle Fabrication and Characterization 
In these studies, two bifunctional environment-dependent linkages were synthesized in 
house and are discussed in greater detail in previous accounts. In both linkages, one side group is 
functionalized with a common chemotherapeutic, gemcitabine, and the other an acrylate group 
for fabrication into the polymeric matrix upon PRINTing (Figure 5.1). The pH- and reduction-
dependent pro-drugs (henceforth denoted iPr-GEM and SS-GEM, respectively) were loaded into 
the pre-particle solution (PPS) at 20 wt % of solids for either fabrication of 80 nm x 80 nm x 320 
nm PRINT hydrogels. As a side note, diethyl silyl gemcitabine (Et-GEM) acrylate was also 
tested for functionalization within hydrogel PRINT NPs at an equivalent weight percent; 
however, due to rapid drug dissolution while harvesting from PVOH in cold buffer solution (pH 
7.4 and 9.0 tested) , the pro-drug was not pursued further. Additionally it should be noted that 
due to drug-incorporation, the weight percentage of HP4A was cut by 20 % in order to maintain 
3.5 wt % total solids in the isopropanol PPS (Table 5.1). A decrease in primary monomer and 
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subsequent reduction in hydrophilic monomer : cross-linker ratio may alter the modulus of these 
drug-loaded nanoparticles. Overall, fabrication of both nanoparticle sets was successful and the 
particles exhibited a similar size range, polydispersity, and zeta-potential as previously noted 
(Table 5.2). Upon SEM imaging, both pro-drug loaded nanoparticle types displayed similar size 
and shape to previous 80 nm x 80 nm x 320 nm particles that lack pro-drug (Figure 5.2). 
 
Figure 5.1 Base chemotherapeutic gemcitabine (top) and subsequent derivatives: diisopropyl silyl ether acrylate 
(iPr-GEM; middle) and reducible disulphide acrylate (SS-GEM; bottom). 
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Table 5.1 Composition of drug-loaded PRINT NPs 
 
Table 5.2 Dynamic light scatting of prodrug-loaded 80 nm x 80 nm x 320 nm NPs 
 
  
Figure 5.2 Scanning electron microscopic images of harvested iPr-GEM NPs (left) and laminated SS-GEM (right) 
loaded 80 nm x 80 nm x320 nm [scale bar on right = 1 um]. 
Monomer 
Pro-drug NPs 
Weight % 
Blank NPs 
Weight % 
2-aminoethyl methacrylate HCl (AEM) 20 20 
PEG700 diacrylate 10 10 
2,4,6 trimethylbenzoyl diphenylphosphine oxide (TPO) 1 1 
Isopropyl-GEM or Disulphide-GEM 
(iPr-GEM or SS-GEM) 
20 0 
Hydroxy (PEG)4 acrylate (HP4A) 49 69 
Total 100 100 
80 x 320 Type 
Z-avg 
(nm) 
PdI 
ZP 
(mV) 
iPr-GEM 249 ± 4 0.02 ± 0.01 36 ± 5 
SS-GEM 274 ± 2 0.11 ± 0.02 35 ± 7 
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5.2.2 Gemcitabine Release from Hydrogel Nanoparticles 
In order to quantify total drug-loading and rate of release of the two linkages from the 
PRINT hydrogels, drug dissolution and HPLC analysis was conducted. A loading of active 
gemcitabine was observed at approximately 100 µg and 50 µg of gemcitabine per mg of NP for 
iPr-GEM and SS-GEM, respectively. Based upon this, the loading efficiency 
( 
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑀𝑎𝑠𝑠 𝐺𝐸𝑀 𝑣𝑖𝑎 𝐻𝑃𝐿𝐶 𝑜𝑓 𝑇𝑜𝑡𝑎𝑙 𝐷𝑟𝑢𝑔 𝑅𝑒𝑙𝑒𝑎𝑠𝑒
𝐻𝑦𝑝𝑜𝑡ℎ𝑒𝑡𝑖𝑐𝑎𝑙 𝐶ℎ𝑎𝑟𝑔𝑒 𝑀𝑎𝑠𝑠 𝐺𝐸𝑀 𝑣𝑖𝑎 𝑃𝑃𝑆
 ) was calculated at approximately 90% and 50% 
for the iPr-GEM and SS-GEM, respectively. In time-dependent release studies for iPr-GEM 
loaded NPs, drug release was minimal at physiological conditions (pH 7.4) with less than 20% 
over five days. In the same time interval, in conditions representative of the subcellular late 
endosome (pH 5.0), sustained drug release of up to 80% was observed (Figure 5.3). Expanding 
on these results, it is of interest to note that due to poor lymphatic drainage and tissue 
oxygenation in the tumor bed, cancerous tissue is often acidic in nature (pH < 7).
15,16
 In the case 
of iPr-GEM loaded NPs, passive targeting to the tumor site may elicit drug release and upon 
endocytosis, sustained cell-specific drug delivery can be obtained. In the case of SS-GEM, no 
detectable drug release was observed at extracellular reducing conditions (1μM GSH); yet, burst 
release was observed at cytoplasmic conditions (5 mM GSH) with over 50% in the first eight 
hours and a sustained release of 70% over the next five days (Figure 5.4). 
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Figure 5.3 Release of free gemcitabine from iPr-GEM loaded 80 x 320 nm NPs upon dissolution as quantified by 
HPLC (time points: 0, 1, 4, 24, 48, and 120 hours). 
 
Figure 5.4 Release of free gemcitabine from SS-GEM loaded 80 x 320 nm NPs upon dissolution in 5 mM 
glutathione as quantified by HPLC (time points: 0, 1, 4, 24, 48, and 120 hours). 
5.2.3 Cytotoxicity of Gemcitabine-Loaded PRINT NPs 
The cytotoxicity of SS-GEM drug-loaded 80nm x 80 nm x 320 nm NPs was tested and 
dosed onto three different cancer cell-lines: 344SQ (mouse non-small cell carcinoma), GFP-
expressing A549 (human non-small cell lung carcinoma), and A431 (human epidermoid 
carcinoma). Important to note that the iPr-GEM was not tested for cytotoxicity and future studies 
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were tabled due to the inability to surface modify NPs for in vivo function (PEGylation and 
acetylation) without losing the majority of drug in reaction and wash solutions. However, SS-
GEM loaded NPs exhibited drug retention during modification and deemed suitable for in vitro 
testing. In previously denoted cell-lines, free gemcitabine exhibited half maximal inhibitory 
concentrations (IC50) at approximately 4 nM and free SS-GEM exhibited an IC50 between 15-100 
nM (Table 5.3). The diminished cytotoxicity of the pro-drug is likely due to necessary disulphide 
reduction and subsequent conversion to active gemcitabine prior to expressing an apoptotic 
effect. To this end, the SS-GEM loaded NPs exhibited significantly lower toxicity towards all 
cancer cell-lines. The reduced NP toxicity is most likely due to necessary cellular endocytosis, 
drug conversion, and diffusion prior to gemcitabine exhibiting an apoptotic effect. 
Table 5.3 IC50 values of Gemcitabine in Three Cancer Cell-lines 
Drug Form 344SQ GFP-A549 A431 
Free Gemcitabine 4 3 4 
Pro-drug Gemcitabine 60 15 100 
Pro-Drug Loaded 
80 nm x 80 nm 320 nm 
500 125 ND* 
*IC50 not detected    
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Figure 5.5 Cytotoxicity of SS-GEM loaded 80 x 320 nm NPs dosed onto 344SQ (mouse non-small cell lung 
carcinoma) cells with approximate IC50 values of 4, 60, and 500 nM for the free-gemcitabine, SS-GEM pro-drug, 
and SS-GEM loaded NPs, respectively.  
 
Figure 5.6 Cytotoxicity of SS-GEM loaded 80 x 320 nm NPs dosed onto A549 (GFP-expressing human non-small 
cell lung carcinoma) cells with approximate IC50 values of 3, 15, and 125 nM for the free-gemcitabine, SS-GEM 
pro-drug, and SS-GEM loaded NPs, respectively. 
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Figure 5.7 Cytotoxicity of SS-GEM loaded 80 x 320 nm NPs dosed onto A431 (human epidermoid carcinoma) cells 
with approximate IC50 values of 4 and 100 nM for the free-gemcitabine and SS-GEM pro-drug, respectively. No 
IC50 for drug loaded NPs was quantified. 
5.3 Materials and Methods 
5.3.1 Materials 
2-aminoethyl methacrylate hydrochloride (AEM), reduced glutathione (GSH), 
dithiothreitol (DTT), diphenyl (2,4,6-trimethylbenzoyl) phosphine oxide (TPO), poly (ethylene 
glycol) diacrylate (Mn 700) (PEG700DA), trypsin, ethylenediaminetetraacetic acid (EDTA), and 
sucrose were obtained from Sigma-Aldrich. Thermo Scientific HyClone fetal bovine serum 
(FBS), isopropanol, sterile water, dimethylformamide (DMF), Dulbecco’s phosphate buffered 
saline (pH 7.4), 1X phosphate buffered saline (PBS), sodium hydroxide potassium acid phthalate 
buffer (pH 5.0), and Dulbecco's Modified Eagle's Medium (DMEM) were purchased from Fisher 
Scientific. Polyvinyl alcohol (Mw 2000) (PVOH) was bought from Acros Organics. Human 
epidermoid carcinoma (A431) cells were purchased from American Type Culture Collection. 
Murine lung adenocarcinoma (344 SQ) cells were graciously provided by the laboratories of Dr. 
Chad Pecot. GFP-expressing human non-small cell lung carcinoma (A549) cells were kindly 
provided by the UNC Animal Core. 80 nm x 80 nm x 320 nm PRINT molds were acquired from 
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Liquidia Technologies. As described in previous accounts, tetraethylene glycol monoacrylate 
(HP4A) was synthesized in-house. 
17
  
5.3.2 Pro-drug Incorporation and Particle Characterization 
The pro-drug loaded 80 nm x 80 nm x 320 nm were fabricated with similar methods as 
indicated in section 4.4.2 with a few minor changes. The SS-GEM and iPr-GEM pro-drugs were 
dissolved in DMF (40 – 100 mg /mL) prior to addition into the pre-particle solution. Upon 
drawing the polymeric film on the R2R, the heat gun temperature was increased in order to 
evaporate poorly volatile DMF prior to mold lamination. All other procedures, such as 
lamination to PVOH, were kept the same. 
In effort to reduce premature gemcitabine release when harvesting and purifying iPr-
GEM loaded NPs, a number of procedures were put into place to diminish premature drug 
release. First, the harvesting solution (pH 7.4) was kept at 4°C. In addition, the NP solution was 
purified by centrifugation methods utilizing chilled pH 7.4 buffer. As well, complete 
characterization by TGA and DLS was completed as quickly as possible. As will be described in 
greater detail in section 5.3.3, both total and time-dependent drug release was initiated 
immediately upon concentration assessment by TGA. 
5.3.3 Drug Release and HPLC Quantification 
Total drug release and time-dependent drug release studies were assessed by simple drug 
dissolution methods. Total drug release of iPr-GEM NPs was assessed by first resuspending NPs 
at 1 mg / mL (200 µL) in pH 2.0 buffer and incubating in a 1.5 mL Eppendorf for 24 hours at 
37 °C on a shaker plate (Eppendorf, 1400 rpm). At the time point, an aliquot of the particle 
solution (80 µL) was removed from the incubating solution, placed into another Eppendorf tube, 
and centrifuged (Eppendorf 5417C, 14000 rpm) for 30 minutes. The supernatant (60 µL), 
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containing the released gemcitabine, was put into another Eppendorf and placed directly into 
storage at -20°C. Total drug release of SS-GEM loaded NPs was assessed utilizing the exact 
same methods except the particles were initially resuspended in a reducing solution of DTT (100 
mM). Time-dependent drug release of iPr-GEM loaded NPs was assessed by first resuspending 
NPs at 1 mg / mL (1 mL) in either pH 5.0 or pH 7.4 buffer. The dissolution procedure was 
identical to total drug release studies except multiple time points were collected at 1, 4, 8, 24, 48, 
and 120 hours. The time-dependent drug release of SS-GEM loaded NPs was identical that of 
iPr-GEM except the NPs were initially resuspended in a 5 mM glutathione solution. 
In order to quantify the mass of gemcitabine released in total and over time, HPLC 
analysis was utilized. HPLC was run on an Agilent 1200 series HPLC system. The mobile phase 
consisted of mixtures of H2O + 0.1% TFA (solvent A) and acetonitrile + 0.1% TFA (solvent B). 
The elution protocol for released gemcitabine consisted of a gradient starting at 100:0 (A to B) 
and finishing at 97.5:2.5 (A to B) over 10 minutes. The analyte was eluted at a flow rate of 1 mL 
/ min and monitored at a wavelength of 267 nm. The peak for gemcitabine eluted at 
approximately 8 minutes. In order to quantify drug release, a standard curve was created from a 
0.5 mg / mL gemcitabine·HCl water solution with 10 standard dilutions (Figure A.1-A.4).  
5.3.4 Cytotoxicity Studies 
Cells were seeded in 200 µL of media [RMPI 1640 Medium supplemented with 10% FBS] 
at a density of 5000 cells /cm
2
 into a 96-well micro-titer plate. Cells were allowed to adhere for 
24 h and then incubated with SS-GEM NPs, free gemcitabine, or free SS-GEM prodrug at 
concentrations ranging from1,000 µg/mL to 0.061 ng/mL for 72 h at 37 °C in a humidified 5% 
CO2 atmosphere. After the incubation period, all medium/particles were aspirated off cells. 100 
µL fresh medium was added back to cells followed by addition of 100 µL Cell Titer-Glo® 
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Luminescent S8 Cell Viability Assay reagent. Plates were placed on a microplate shaker for 2 
min and incubated at room temperature for 10 minutes to stabilize luminescent signal. The 
luminescent signal was then recorded (Molecular Dynamics SpectraMax M5 plate reader) and 
the viability of the cells were expressed as a percentage of the viability of cells grown in the 
absence of particles. 
5.4 Conclusions 
Significant work has been conducted into the optimization of PRINT hydrogels for 
tumoritropic delivery. With the optimal particle, it was of great interest to load a potent and 
commonly used chemotherapeutic, gemcitabine, into the polymeric matrix through 
environmental-dependent linkages. In this account two linkages were studied (1) a reversible 
disulphide linkage dependent on cytosolic reducing conditions for cleavage and (2) a pH-
dependent silyl ether linkage dependent on acidic late-endosome conditions for cleavage. In drug 
dissolution, immediate burst release of the SS-GEM loaded NPs was observed when in 
cytoplasmic reducing conditions, yet, negligible release was observed in extracellular reducing 
conditions. The iPr-GEM linkage displayed a sustained release profile over the course of 5 days 
with minimal release in physiological conditions. In cytotoxicity studies, encouraging toxicity 
was observed for SS-GEM loaded NPs against A549 human NSCLC. In future experiments, SS-
GEM loaded NPs will be tested in human A549 xenograft and orthotopic mouse models. 
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CHAPTER 6 FUTURE WORK AND SUMMARY 
6.1 Hydrogel PRINT Nanoparticles for the Treatment of Cancer  
As demonstrated in this work, nanoparticle surface modification, alterations in NP size, 
and variations in disease model can have dramatic effects on particle-blood interactions and 
subsequent in vivo biodistribution. Designing PRINT NPs with a dense PEG layer is paramount 
for enhancing macrophage resistance, inhibiting protein binding, and extending retention in the 
blood compartment.
1
 Interestingly, PRINT NPs require significantly lower PEG coverage upon 
comparison to other nanoparticles throughout literature. Most likely, the hydrophilic nature of 
the hydrogel promotes biocompatibility and helps avoiding immune recognition. When actively 
targeting PEGylated PRINT NPs, optimizing ligand surface density is vital. With increasing 
ligand coverage, NP internalization in target and off-target cells increased dramatically in vitro; 
as well, upon IV-administration, blood retention quickly diminished and particle accumulation 
into an EGFR-overexpressing flank tumor increased. However, it was beyond question that the 
determinant factor promoting tumor deposition was nanoparticle size, as the 55 nm x 60 nm NP 
outperformed all types (targeted 80 x 320, non-targeted 80 x 320, and targeted 55 x 60 nm). Even 
with superior tumor deposition of the non-targeted 55 x 60 nm NP, it is premature to suggest that 
this will without a doubt translate to greater efficacy as targeting may enhance in vivo cancer cell 
uptake, subsequently, improving efficacy. Even with these optimizations in PRINT NPs, 
nanoparticles should only be utilized in treating cancers prone to macromolecular accumulation 
as the degree of EPR effect varies immensely from one cancer type to another.  
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Exhaustive evaluation of disease models prone to NP accumulation may translate to more 
immediate therapeutic benefit. In our studies, NP tumor accumulation varied dramatically 
between different murine cancer models. A murine non-small cell lung isograft, 344SQ, 
displayed superior particle sequestration over all other flank cancer cell-types and orthotopic 
disease models of metastatic NSCLC revealed preferential particle accumulation in diseased 
tissue. With the optimized carrier and model, ongoing studies encompass the incorporation of 
gemcitabine pro-drugs into the particle matrix and how environmental stimuli can be used to 
release the toxic cargo. As current studies progress, obstacles will arise, some of these can be 
predicted and others not. Potentially, the most foreboding challenge may arise from the same 
poly (ethylene glycol) coating that has led to such remarkable tumor accumulation. 
6.2 The PEGylation Paradox 
Optimizing the PEGylation density has led to unprecedented sequestration of PRINT NPs 
inside murine tumors and yet it is currently unknown whether this will prove beneficial in the 
realm of drug delivery. The reasoning behind the uncertainty lies within the superior resistance 
of PEGylated particles to be internalized in non-phagocytic cell-lines, as would be cancer cells. 
With the current pro-drugs being assessed, both require NPs to be internalized within a cell for 
drug release, whether in the cytosol or late endosome. While some drug release may occur in the 
slightly acidic extracellular tumor environment, the degree of release in vivo is not currently 
known. In order to counter this potential issue, alternative methods of drug delivery once at the 
tumor site should be devised in case of therapeutic failure. 
 Alternatives to poly (ethylene glycol) coatings or adaptions of it may prove beneficial. A 
number of alternative surface coatings to PEG have been created, such as poly (vinyl alcohol), 
 124 
poly-N-vinylpyrrolidone, and poly (amino acid) s.
2-5
These alternative coatings display similar 
characteristics of PEG in reducing RES recognition and extending blood circulation.
2
 As well, 
PEG substitutes may become a necessity as PEG-specific IgM antibodies have been observed 
after initial dosage of stealth liposomes, leading to substantially reduced circulation half-life in 
follow-up IV-administrations.
6,7
 However, in most cases, alternative coatings still require 
covalent attachment; therefore, this may not overcome issue related to particulate cell 
internalization once at the tumor site. Adsorption of PEG to the surface of the particle may be 
useful over covalent attachment as the coating can shed over time, leaving a positive surface 
charge on the NP, and promoting cellular internalization which has been observed in previous 
studies.
8 
However, non-covalent interactions of a PEG surface coating may result in stability and 
storage issues prior to particle injection. Dr. Leaf Huang, a key designer of the PEGylated 
liposome, has described that a covalently attached sheddable-PEG coating may prove invaluable 
in facilitating successful drug delivery to tumor cells.
6
 The sheddable-coating may be possible 
through the use of PEG-NP linkages that, like the pro-drugs linkages previously discussed, can 
be environmentally dependent. To this effect, several linkages have already been developed that 
may yield successful release of the PEG coating upon accumulation in the tumor bed.  
The development of pH-sensitive linkages that rapidly release PEG at slightly acidic 
conditions is of upmost importance for effective drug delivery within cancer cells (Figure 6.1).
2
 
β-thiopropionate linkages have proven to be extremely sensitive to changes in pH with reported 
degradations of up to 97% at pH 5.5 and no observable cleavage at physiological conditions 
(37°C; pH ~7.4) after 24 hours.
2,9
 Perhaps the most commonly used acid-sensitive linker utilizes 
hydrazone chemistry. In one account utilizing a DNA/polycation polyplexes, no-deshielding of 
PEG from the NP was observed after 4h at physiological conditions with complete deshielding at 
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1h at pH 5.
2,10
 The most promising may be diorthoester chemistry, as it one of the most studied 
linkages and very mild reductions in pH (tumor microenvironment) promote rapid hydrolysis and 
PEG shedding. 
2,6,11-13
  
 
Figure 6.1 Diorthoester (A), hydrazone (B), and β-thiopropionate (C) pH-sensitive linkages commonly used with 
sheddable PEG and subsequent hydrolysis reactions (R1 = PEG, R2 = NP).
2 
 Even with this potential issue and others may come along, the delivery of PRINT 
nanoparticles to cancerous tissue continues to be an exciting and fruitful endeavor. The use of 
PRINT technology allows for such fine control over particle design parameters that we have 
been able to improve tumor accumulation from less than 1% in the year 2010 to upwards of 50% 
in 2015. In general, these accomplishments were made possible through the advancement of the 
particle surface characteristics and size, as well, the study of what animal models are best fit for 
particulate therapy. Needless to say, the future of PRINT in the field of cancer treatment is very 
promising. 
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6.3 Summary 
6.3.1 PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding, 
Macrophage Association, Biodistribution, and Pharmacokinetics 
The impacts of NP surface modification with poly (ethylene glycol): extending NP blood 
circulation, inhibiting protein binding to the carrier, and diminishing overall RES recognition is 
well known.
14
 However, the degree of PEGylation on a particulate surface, or PEGylation 
density, to successfully promote these in vivo benefits is more elusive. In literature, 
complications arise due to differences in the carrier and major differences in validation and 
because of this, questions remain to be answered. What is the standard manner in which PEG 
density should be reported (PEG/nm
2
, PEG/NP, mol PEG / mass NP, etc.)? What is the optimal 
PEG coverage to promote benefits in vivo? Is this PEG density dependent on the characteristics 
of the carrier? What is the proper method to quantify PEGylation density? These questions 
remain unanswered, for the most part, because there are few ways to accurately quantify PEG 
density.  
In Chapter 2, we attempted to address this issue by developing a method to assess PEG 
density via standard plate-reader analysis of a fluorescently-tagged PEG. The PEGylation density 
on the surface of hydrogel PRINT nanoparticles was varied and the effects on protein adsorption, 
macrophage uptake, and circulation time were observed. Interestingly, the density of PEGylation 
necessary to promote a long-circulating particle was dramatically less than what has been 
previously reported. Overall, the methodology provides a rapid screening technique to predict 
particle behavior in vivo and our results deliver further insight to what PEG density is necessary 
to facilitate long-circulation. 
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6.3.2 Targeted PRINT Hydrogels: The Role of Nanoparticle Size and Ligand Density on Cell 
Association, Biodistribution, and Tumor Accumulation 
Functionalizing nanoparticles with biological entities that bind to over-expressed 
receptors on cancerous cells, termed active targeting, is a major endeavor in the field. Active 
targeting continues to be a hotly studied area due to the potential to preferentially target cancer 
cells over healthy tissue leading to several benefits: improving drug delivery, reducing off-target 
toxicity, and increasing the overall therapeutic index of an API.
15
 However recently, undesired 
consequences of targeting a carrier have begun to arise due to “over-targeting” a carrier; 
examples include unanticipated toxicity of a seemingly non-toxic carrier, alterations in PK/PD, 
and enhanced immunogenicity.
15,16
 Similar to issues addressed in Chapter 2, it was of interest to 
study how ligand density changed the behavior in cell culture and in vivo.  
In Chapter 3, we addressed these issues by fabricating two hydrogel particle types (80 nm 
x 80 nm x 320 nm and 55 nm x 60 nm) with varying amounts of EGFR binding affibody (Z
EGFR
) 
conjugated through a PEG5k-linker. The density of ligand density was varied on both NP types 
and effects on cell uptake, biodistribution, and tumor accumulation were observed. In vitro 
studies revealed direct dependence of cell membrane association and cellular internalization as a 
function of targeting ligand density, nanoparticle dosage, and time. In vivo studies displayed a 
notable inverse relationship between circulation time and ligand density, yet, a direct correlation 
was observed for tumor accumulation. Overall, targeting ligand density and NP size were shown 
to have major impacts on in vivo outcomes. 
6.3.3 Mediating Passive Accumulation with PRINT Nanoparticles: The Effect of Particle Size 
and Tumor Model 
The therapeutic benefit of nanoparticles as drug carriers against cancer has, to this point, 
been of moderate success.
17
 Some researchers indicate that the lack of impact stems from natural 
 128 
lags between academic success and clinical translation, specifically noting antibody drug 
conjugates (ADCs) and the large time interval between its foundation in the 1970’s and its 
current massive success in the year 2015.
18
 Without a doubt, this is a fair and reasonable view. 
Academic discoveries need time to mature, pass through the minds and hands of researchers, and 
have points of controversy and discussion before they can translate to something as complex as 
treating human disease. However, a number of issues currently exist in the field of 
nanoparticulate cancer therapeutics that hinder clinical achievements: (1) improper assessment of 
efficacy in disease models (ex. insufficient data collection in tumor regression/survival studies), 
(2) use of disease models that fail to translate to humans (ex. subcutaneous xenograft mouse 
models, while low in cost and beneficial in a complementary role, are alone insufficient when 
assessing potential clinical success), and (3) large batch-to-batch variance of the carrier (ex. 
changes in drug loading, size, stability). Along with these issues, the field has not truly identified 
the types of cancer most benefited by particle therapy. With these issues in mind, we attempted 
to identify cancer cell-lines that may be the most impacted by the use of nanoparticle therapies.   
In Chapter 4, we manufactured three different particle types: 80 nm x 80 nm x 320 nm, 
80 nm x 80 nm x 180 nm, and 55 x 60 nm surface-modified poly(ethylene glycol) and examined 
how NP size, tumor cell-line, and tumor location affect particle deposition in cancerous tissue. In 
vivo studies revealed that particle size had no effect on blood pharmacokinetic behavior, 
association with cancerous cells, or macrophage resistance. In four different flank tumor mouse 
models, particulate accumulation varied drastically between the different NP types and models. 
Additionally, IHC staining of the four flank models revealed major differences in microvessel 
density, collagen, and tumor-associated macrophage. In orthotopic disease models, 55 nm x 60 
nm NPs preferentially deposited in both primary and metastatic sites in comparison to off-target 
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healthy tissue. While preferential metastatic accumulation is encouraging, assessment of 
therapeutic effect can only be deemed upon efficacy in clinically relevant disease models.   
6.3.4 Environment-Sensitive Drug Release from PRINT Nanoparticles 
Passive and active targeting nanoparticulate strategies may yield improved deposition into 
a solid tumor mass; yet, delivery of an active pharmacological agent is the main goal. While 
several NP technologies utilize drug encapsulation as the method of drug entrapment, diffusion 
out of the particle upon administration promotes higher volume of distribution and systemic 
toxicity.
19,20
 In order to account for this, a number of pro-drug strategies have been developed 
that covalently attach an API to a nanocarrier through a cleavable bond that can be unconjugated 
with a unique stimulus.
21,22
 In the laboratories of DeSimone, two linkages have been developed 
that cleave under pH (silyl ether) or reducing (reversible disulphide) conditions and were 
therefore repurposed for chemotherapeutic / nanoparticle attachment.
23,24 
In Chapter 5, two different linkages (1) silyl ether and (2) a reversible disulphide were 
studied that exhibit bifunctional functionality with gemcitabine, a common nucleoside analogue, 
and an acrylate group for PRINT NP incorporation. The SS-GEM linker revealed burst release 
upon reaching conditions similar to cell cytoplasm, an environment reducing in nature, and 
negligible release in extracellular reducing conditions. The iPr-GEM displayed sustained release 
at acidic conditions, similar to subcellular conditions in the late endosome, and slow release in 
physiological conditions. The advancements made in particle surface characteristics, NP size, 
and tumor model optimization will be combined with these endeavors in pro-drug incorporation 
in effort to test for therapeutic efficacy. 
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APPENDIX 
 
Figure A.1 Chromatogram of gemcitabine·HCl (0.25 mg / mL in sterile water) upon analysis via HPLC (Abs = 267 
nm) with observed elution time of ~ 6.5 min. 
 
Figure A.2 Chromatogram of SS-GEM pro-drug (0.1 mg / mL in sterile water) upon analysis via HPLC (Abs = 267 
nm) with observed elution time of ~ 13.2 min. 
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Figure A.3 Chromatogram of iPr-GEM pro-drug (0.1 mg / mL in sterile water) upon analysis via HPLC (Abs = 267 
nm) with observed elution time of ~ 22.2 min. 
 
 
Figure A.4 Standard curve of gemcitabine (10 standard dilutions) upon analysis via HPLC (Abs = 267 nm). 
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